WO2007140613A1 - Fermented milk product and use thereof - Google Patents
Fermented milk product and use thereof Download PDFInfo
- Publication number
- WO2007140613A1 WO2007140613A1 PCT/CA2007/001010 CA2007001010W WO2007140613A1 WO 2007140613 A1 WO2007140613 A1 WO 2007140613A1 CA 2007001010 W CA2007001010 W CA 2007001010W WO 2007140613 A1 WO2007140613 A1 WO 2007140613A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral formulation
- subject
- yogurt
- disease
- disorder
- Prior art date
Links
- 235000014048 cultured milk product Nutrition 0.000 title description 2
- 239000003094 microcapsule Substances 0.000 claims abstract description 152
- 241000894006 Bacteria Species 0.000 claims abstract description 66
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 238000009472 formulation Methods 0.000 claims abstract description 65
- 238000011282 treatment Methods 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 43
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 39
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 38
- 208000018685 gastrointestinal system disease Diseases 0.000 claims abstract description 38
- 235000015140 cultured milk Nutrition 0.000 claims abstract description 26
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 157
- 235000013618 yogurt Nutrition 0.000 claims description 115
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 89
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 229940072056 alginate Drugs 0.000 claims description 41
- 229920000615 alginic acid Polymers 0.000 claims description 41
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 34
- 235000010443 alginic acid Nutrition 0.000 claims description 34
- 239000006041 probiotic Substances 0.000 claims description 34
- 230000000529 probiotic effect Effects 0.000 claims description 34
- 235000018291 probiotics Nutrition 0.000 claims description 34
- 239000012530 fluid Substances 0.000 claims description 33
- 230000002496 gastric effect Effects 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 208000003200 Adenoma Diseases 0.000 claims description 21
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 20
- 229920001661 Chitosan Polymers 0.000 claims description 19
- 206010009944 Colon cancer Diseases 0.000 claims description 19
- 210000001072 colon Anatomy 0.000 claims description 19
- 210000002784 stomach Anatomy 0.000 claims description 19
- 102000004889 Interleukin-6 Human genes 0.000 claims description 17
- 108090001005 Interleukin-6 Proteins 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 17
- 206010001233 Adenoma benign Diseases 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- 208000029742 colonic neoplasm Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 230000002550 fecal effect Effects 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
- 206010009887 colitis Diseases 0.000 claims description 10
- 235000016709 nutrition Nutrition 0.000 claims description 10
- 241000186000 Bifidobacterium Species 0.000 claims description 8
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 8
- 102100032752 C-reactive protein Human genes 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 238000009534 blood test Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 244000005706 microflora Species 0.000 claims description 7
- 206010003011 Appendicitis Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 230000003187 abdominal effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- 244000199866 Lactobacillus casei Species 0.000 claims description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000009469 supplementation Effects 0.000 claims description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 4
- 241000212468 Lactobacillus plantarum 80 Species 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 4
- 238000004820 blood count Methods 0.000 claims description 4
- 235000013351 cheese Nutrition 0.000 claims description 4
- 210000003979 eosinophil Anatomy 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 239000006174 pH buffer Substances 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- 210000001635 urinary tract Anatomy 0.000 claims description 4
- 208000004998 Abdominal Pain Diseases 0.000 claims description 3
- 208000004804 Adenomatous Polyps Diseases 0.000 claims description 3
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 3
- 208000002881 Colic Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 206010030216 Oesophagitis Diseases 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 208000002389 Pouchitis Diseases 0.000 claims description 3
- 230000001174 ascending effect Effects 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 208000007784 diverticulitis Diseases 0.000 claims description 3
- 208000006881 esophagitis Diseases 0.000 claims description 3
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims description 3
- 235000015243 ice cream Nutrition 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 206010007275 Carcinoid tumour Diseases 0.000 claims description 2
- 241000792859 Enema Species 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 210000000436 anus Anatomy 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 238000002052 colonoscopy Methods 0.000 claims description 2
- 230000001332 colony forming effect Effects 0.000 claims description 2
- 238000002591 computed tomography Methods 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 229940095399 enema Drugs 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 229940044627 gamma-interferon Drugs 0.000 claims description 2
- 230000028709 inflammatory response Effects 0.000 claims description 2
- 235000015141 kefir Nutrition 0.000 claims description 2
- 235000020129 lassi Nutrition 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 235000008476 powdered milk Nutrition 0.000 claims description 2
- 235000013406 prebiotics Nutrition 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 210000001599 sigmoid colon Anatomy 0.000 claims description 2
- 235000020125 yoghurt-based beverage Nutrition 0.000 claims description 2
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 claims 1
- 235000014121 butter Nutrition 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 229960002986 dinoprostone Drugs 0.000 claims 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 description 71
- 230000004083 survival effect Effects 0.000 description 52
- 239000000243 solution Substances 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 31
- 238000012360 testing method Methods 0.000 description 19
- 239000003613 bile acid Substances 0.000 description 18
- 238000003860 storage Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000000872 buffer Substances 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 230000035899 viability Effects 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 14
- 210000000813 small intestine Anatomy 0.000 description 14
- 210000004379 membrane Anatomy 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 210000003608 fece Anatomy 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 7
- 239000000661 sodium alginate Substances 0.000 description 7
- 235000010413 sodium alginate Nutrition 0.000 description 7
- 229940005550 sodium alginate Drugs 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 108010000231 Choloylglycine hydrolase Proteins 0.000 description 5
- 206010058314 Dysplasia Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 5
- 229960003964 deoxycholic acid Drugs 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 208000037062 Polyps Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- 241000147041 Guaiacum officinale Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003858 bile acid conjugate Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 229940099347 glycocholic acid Drugs 0.000 description 2
- 229940091561 guaiac Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005597 polymer membrane Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 108700001666 APC Genes Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010050808 Hyperchromasia Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010049059 Urinary tract infection fungal Diseases 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000025768 adenoma of small intestine Diseases 0.000 description 1
- 108700023471 alginate-polylysine-alginate Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008955 bacterial trafficking Effects 0.000 description 1
- 241000385732 bacterium L Species 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000007444 cell Immobilization Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019625 fat content Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000010148 papillary adenoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- 108010050918 polyhemoglobin Proteins 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1232—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt in powdered, granulated or dried solid form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
Definitions
- TITLE Fermented milk product and use thereof
- the present invention relates to a novel method for encapsulating live bacteria; an encapsulated live bacteria; an oral formulation for probiotic therapy and method of treatment thereof.
- a well balanced gut microflora is known to contribute to the maintenance of a healthy intestinal mucosa.
- the density of gastrointestinal (Gl) microflora increases from the stomach to the large intestine reaching 1010 - 1012 cfu/g in the colon.
- Gl gastrointestinal
- One of the most important groups of bacteria for intestinal health is lactic acid bacteria (LAB) (Adolfsson, O. et al., (2004), American Journal of Clinical Nutrition 80:245-256).
- LAB are considered probiotic; live microorganisms that remain in the Gl tract to benefit the host (Adolfsson, O. et al., (2004), American Journal of Clinical Nutrition 80:245- 256; Roberfroid, 2000).
- probiotic yogurt has significant clinical benefits (Donaldson, M. S., (2004), Nutrition Journal 3:19). It is estimated that a decrease of at least 60-70 percent in breast, colorectal, and prostate cancers and 40-50 percent in lung cancer would occur when a diet is complied with (according to the anti-cancer diet guidelines) which includes probiotic yogurt products.
- yogurt In order to be labeled probiotic, yogurt must contain a cell load of at least 107 cfu/g at the time of manufacture (Chandan.R.C. et al., (1993), Ed Hui, Y H, VCH Publishers, lnc , New York1-56).
- the transit of free bacteria through the gastrointestinal tract is often problematic because of low pH conditions, enzymatic digestion and very few probiotic cells finally reach their targeted site.
- the challenge here consist in producing a support allowing successful storage and transport of bacteria which could, if added to one's diet, constitute an alternative but effective treatment to various medical issues caused by an imbalance between desirable and undesirable microorganisms in the Gl microflora.
- an oral formulation to improve a patient gastrointestinal microflora which comprises coated microcapsule containing bacteria in suspension in a probiotic acceptable carrier, wherein said coated microcapsule comprises an encapsulated bacteria in a semipermeable capsule coated with poly-L-Lysine (PLL) and alginate and is also resistant in gastrointestinal conditions.
- PLL poly-L-Lysine
- the bacteria may be chosen from Lactobacilli cells, Bifidobacterium cells, Lactobacillus plantarum 80, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus Rhamnosus, Lactobacillus, more particularly from Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium, Lactobacillus plantarum 80, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus Rhamnosus, Lactobacillus GG.
- the bacteria is live.
- the microcapsule is made of a material chosen from alginate-poly-L-Lysine-alginate (APA), alginate-chitosan (AC), alginate pectinate polylysine pectinate alginate (APPPA), alginate polyethylene glycol alginate (APEGA), alginate chitosan genipin alginate (ACGA).
- the probiotic acceptable carrier is at a substantially basic pH to further protect from gastrointestinal fluids.
- the probiotic acceptable carrier is chosen from a food supplement or food.
- the food carrier is chosen from yogurt, ice cream, cheese, chocolate, nutritional bars, cereal, milk, infant formulation, fruit juices.
- a method for probiotic therapy of a patient for improving gastrointestinal microflora which comprises orally administering the oral formulation of the present invention.
- the patient is suffering from a disease or disorder chosen from breast cancer, colorectal cancer, prostate cancer, lung cancer, urinary tract infections, yeast infections and inflammatory bowel diseases (IBD),
- a disease or disorder chosen from breast cancer, colorectal cancer, prostate cancer, lung cancer, urinary tract infections, yeast infections and inflammatory bowel diseases (IBD)
- CD Crone's diseases
- an oral formulation comprising: a microcapsule containing bacteria; and a fermented milk carrier.
- the microcapsule may comprise a semipermeable capsule comprising poly-L-Lysine (PLL) and alginate and wherein the microcapsule is resistant to degradation in gastrointestinal conditions.
- PLA poly-L-Lysine
- the bacteria may be Lactobacilli bacteria or Bifidobacterium bacteria.
- the Lactobacilli bacteria are selected from the group consisting of Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum 80, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus Rhamnosus,
- a method for treatment or prevention of a disease or disorder in a subject in need thereof or for nutritional supplementation of a subject comprising orally administering to the subject the oral formulation of the present invention.
- the oral formulation of the present invention for the preparation of a medicament for the treatment or prevention of a disease or disorder or for the preparation of a nutritional supplement.
- a fermented milk carrier i) for use as a prebiotic carrier in increasing the efficacy of microencapsulated bacteria in the treatment of a disease or disorder in a subject or ii) for preparation of a medicament for the treatment of a disease or disorder in a subject; wherein optionally the carrier is used in the oral formulation of the present invention.
- the subject may be a mammal, optionally a human.
- the disease or disorder includes a gastrointestinal disease or disorder.
- the gastrointestinal disease or disorder includes an inflammation gastrointestinal disease or disorder such as Inflammatory Bowel Disease (IBD), Crohn's Disease, colitis, enteroinvasive colitis, C. difficile colitis, Ulcerative Colitis (UC), Inflammatory Bowel Syndrome (IBS), pouchitis, diverticulitis, gastroenteritis, colic, appendicitis, appendicitis, ascending colangitis, esophagitis, gastritis, or enteritis.
- the disease or disorder includes cancer, such as breast cancer, colorectal cancer, prostate cancer, lung cancer, colon cancer and inflammation-related colon cancer, including adenoma, carcinoma, leiomyosarcoma, carcinoid tumor, or squamus cell carcinoma. Lactobacillus GG, Bifidobacterium infantis, Bifidobacterium breve, Bifidobacterium Iongum, Bifidobacterium bifidum.
- the bacteria may be live.
- the bacteria may be present in a range from 109 to 1012 colony forming units (CFU).
- the microcapsule may comprise a material selected from the group consisting of alginate-poly-L-Lysine-alginate (APA), alginate-chitosan
- AC alginate pectinate polylysine pectinate alginate
- AEGA alginate polyethylene glycol alginate
- ACGA alginate chitosan genipin alginate
- the fermented milk carrier may comprise a basic pH buffer and protects the bacteria and/or the microcapsule from gastrointestinal fluids.
- the basic pH buffer may be between pH 7-9.
- the fermented milk carrier may comprise a food supplement or food, such as yogurt, cheese, milk, powdered milk, kefer or a fermented milk formulation.
- the yogurt may be selected from the group consisting of plain yogurt, flavored yogurt, yogurt beverage, Dahi, Dadiah, Labneh, Bulgarian Yogurt, Tarator, Cacik, Lassi and Kefir.
- the yogurt may comprise 1-10 grams of microencapsulated bacteria per 100 grams of yogurt, optionally 5-10 grams of microencapsulated bacteria per 100 grams of yogurt, optionally 8-10 grams of microencapsulated bacteria per 100 grams of yogurt.
- the yogurt may comprise 4.2 grams of harvested bacteria in 100 mL of 1.65% alginate solution.
- the oral formulation of the present invention may be use in nutritional supplementation of a subject or for use in preventing or treating a disease or disorder in a subject.
- the disease or disorder includes inflammation of tissue in bowel, colon, sigmoid colon, rectum, appendix, anus, esophagus, stomach, mouth, liver, billiary, tract or pancreas, including inflammation of colon.
- the inflamed tissue or colon comprises increased interleukins and cytokines compared to non-inflamed tissue or colon, such as up- regulated inflammatory response and markers compared to non-inflamed tissue or colon, such as tumor necrosis factor- ⁇ [TNF- ⁇ ], interleukin-1 [IL-1], IL-6, IL-12, and ⁇ -interferon in macrophages.
- TNF- ⁇ tumor necrosis factor- ⁇
- IL-1 interleukin-1
- IL-6 interleukin-1
- IL-12 IL-12
- ⁇ -interferon in macrophages ⁇ -interferon in macrophages.
- the disease or disorder includes a urinary tract related disease or disorder.
- the urinary tract related disease or disorder includes a urinary tract infection or a yeast infection.
- a method of medical treatment of an inflammatory gastrointestinal disease or disorder in a subject in need thereof comprising detecting the presence of inflammatory gastrointestinal disease or disorder in the subject, wherein if inflammatory gastrointestinal disease or disorder is detected, then administering the formulation of any one of claims 1 to 13 to the subject.
- the detecting step may comprise determining the presence of inflammatory gastrointestinal disease or disorder in the subject with a biopsy of the subject's tissue or a blood test of the subject, such as detection of: elevated C Reactive Protein (CRP), increased Erythrocyte Sedimentation Rate (ESR), elevated neutrophil count, elevated eosinophil count, elevated monocyte count, elevated white blood cell count (WBC), elevated immunoglobulin count or elevated IgA, compared to a subject not having inflammation.
- CRP C Reactive Protein
- ESR Erythrocyte Sedimentation Rate
- WBC white blood cell count
- IgA immunoglobulin count
- a method of medical treatment of inflammation- related colon cancer in a subject in need thereof comprising detecting the presence of inflammation-related colon cancer in the subject, wherein if cancer is detected, next administering the formulation of the present invention.
- the detecting step may comprise determining the presence of cancer in the subject using fecal occult blood (FOB), visible protrusion adenomatous polyps from the mucosal surface, digital rectal exam, colonoscopy, sigmoidiscopy, abdominal series radiograph with contrast, double contrast enema abdominal radiograph or abdominal CT scan.
- the detecting step may comprise determining the presence of cancer in the subject with a blood test of the subject comprising detection of elevated carcinoembryonic antigen (CEA) compared to a subject not having cancer.
- CEA carcinoembryonic antigen
- the detecting step may comprise determining the presence of cancer in the subject with a biopsy of the subject's tissue or a blood test of the subject, such as detection of: elevated C Reactive Protein (CRP), increased
- ESR Erythrocyte Sedimentation Rate
- WBC high immunoglobulin count or elevated IgA, compared to a subject not having cancer, such as adenoma or carcinoma.
- an oral formulation for the treatment and/or prevention of a disease and/or disorder which comprises coated microcapsule containing bacteria in suspension in a fermented milk probiotic acceptable carrier, wherein said coated microcapsule comprises encapsulated bacteria in a semipermeable capsule coated with poly-L-Lysine (PLL) and alginate and is also resistant in gastrointestinal conditions.
- PLL poly-L-Lysine
- the expression “mechanically resistant” is referring to an intrinsic construction's capacity of a microcapsule which allows to maintain its original structure and shape against physical and/or mechanical stresses in a particular environment.
- the expression “gastrointestinal conditions” is referring to the various mechanical stresses of the gastrointestinal tract and to the different acidity levels of the gastrointestinal fluids which ingested substances undergo.
- Fig. 1 left, illustrates freshly prepared empty APA microcapsules whereas Fig. 1 , right, illustrates freshly prepared APA microcapsules loaded with L. acidophilus cells.
- Fig. 2 is a photomicrograph of four different stages of APA microcapsules.
- photomicrograph (a) freshly prepared empty APA microcapsules are shown whereas in photomicrograph (b), they were loaded with L. acidophilus.
- Photomicrograph (c) is an illustration APA microcapsules loaded with L. acidophilus cells after 76 hours of incubation in MRS broth and 370 rpm in vitro shaking at 37°C.
- Fig. 3 illustrates empty APA microcapsules exposed to shaking at 150 rpm at 37°C in three different conditions.
- the microcapsules were introduced in SGF (pH 1.98) for 3 hrs.
- they were incorporated in
- Fig. 4 is a graph of the mechanical stability of empty APA microcapsules at various exposure times in simulated gastric fluid (SGF) (pH 1.98) and simulated intestinal fluid (SIF) (pH 6.5) after shaking at 150 rpm at 37 0 C.
- SGF gastric fluid
- SIF simulated intestinal fluid
- Fig. 5 is a photomicrograph of various APA microcapsules loaded with L. acidophilus cells, exposed to mechanical shaking of 100 rpm at
- Y1 storage was in 2% M. F. yogurt for 1 week.
- P1 storage was in 0.85% physiological solution for 1 week.
- Y2) storage was in 2% M. F. yogurt for 2 weeks.
- P2) storage was in 0.85% physiological solution for 2 weeks.
- Y3) storage was in 2% M. F. yogurt for 3 weeks.
- P3) storage was in 0.85% physiological solution for 3 weeks.
- Y4) storage was in 2% M. F. yogurt for 4 weeks and in P4), storage was in 0.85% physiological solution for 4 weeks.
- Fig. 6 A) is a graph of the viability of live L. acidophilus cells in
- Fig. 6 B is a graph illustrating the retention capacity of APA microcapsules.
- the number of viable L. acidophilus bacteria in the supernatant of storage media gives an indication of how many L acidophilus bacteria have leaked from the microcapsules.
- the APA microcapsules loaded with L. acidophilus cells were stored in 0.85% physiological solution for 4 weeks at 4 0 C. No mechanical stress was applied.
- Fig. 7 is a graph evaluating the survival of APA encapsulated L. acidophilus cells in pH 2, 3, 4, 6 and 8 in presence of 2% M. F. yogurt at 37°C.
- Fig. 8 is a graph effectuating a comparison of the survival of APA encapsulated and free L. acidophilus cells in conditions simulating the stomach supplemented with 2% M. F. yogurt at 37 0 C.
- Fig. 9 displays photomicrographs of freshly encapsulated empty capsules and capsules loaded with L. acidophilus cells of 550 ⁇ 26 ⁇ m in size and magnification of 2.5x using light microscopy. .
- Left Photomicrograph of freshly prepared empty AC microcapsules(size 550 ⁇ 26 ⁇ m, magnification: 2.5x).
- Right Photomicrograph of freshly prepared AC microcapsules loaded with L. acidophilus cells.
- Fig. 10 shows three comparative photomicrographs of freshly prepared microcapsules.
- Figure 10. (a) Photomicrograph of freshly prepared empty AC microcapsules, (b) Photomicrograph of freshly prepared AC microcapsules loaded with L. acidophilus, (c) Photomicrograph of AC microcapsules loaded with L.
- FIG. 11 displays three photomicrographs of AC microcapsules exposed to simulated gastrointestinal fluid (SGF) (pH1.98) for 3 hours (11a), to SGF for 12 hours (11b) and to simulated intestinal fluid (SIF) (pH6.5) for 24 hours.
- SGF simulated gastrointestinal fluid
- SIF simulated intestinal fluid
- Figure 11 Photomicrographs of AC microcapsules loaded with L acidophilus cells exposed to shaking at 150 rpm at 37 0 C: (a) in SGF (pH 1.98) for 3 hrs. (b) in SGF (pH 1.98) for 12 hrs. (c) in SGF (pH 1.98) for 3 hrs and in SIF (pH 6.5) for 24 hrs. (Magnification: 6.3x).
- Fig. 12 further demonstrates physical property of exposed microcapsules to a combination of simulated fluids.
- Fig. 13 illustrates the survival of encapsulated bacterial cells in SGF with and without addition of 2% M. F. yogurt as well as the survival of free bacteria contained in the yogurt. Comparison of the survival of AC (chitosan 10) encapsulated and free L. acidophilus cells using Simulated Human Intestinal Microbial Ecosystem - conditions simulating the stomach supplemented with 2% M. F. yogurt at 37 0 C.
- Fig. 14 displays survival of AC encapsulated and free bacterial cells obtained by exposure to simulated intestinal fluid conditions.
- Fig. 15 is a comparative study - survival of AC 10 encapsulated L acidophilus in presence and of 2% M. F. yogurt at 4 0 C and mechanical shaking of 100 rpm.
- Fig. 16 illustrates comparative study of microencapsulated L acidophilus bacterial cells viability in various chitosan concentrations and polymers (0.5%/K ) , 0.25%/K), 0.1 %/10) in 2% M. F. yogurt with free L. acidophilus bacterial cells in 0.85% saline during 4 weeks of mechanical shaking at 100 rpm at 4 0 C.
- Fig. 17 Viability of free L. acidophilus cells in 2%M.F. plain yogurt in buffers: pH2, pH3, pH4, pH6 and pH8.
- Fig. 19 is a photomicrograph of APA microcapsules loaded with Lactobacillus acidophilus bacterial cells at 77* magnification and (b) at 112 ⁇ magnification, (size 433um ⁇ 67)
- Fig. 20 illustrates the effect of the treatment on animal body weights in the Min mouse. Data represent the mean ⁇ SEM per group.
- Fig. 21 illustrates the changes in the expression levels of antiinflammatory interleukin-6 examined during treatment at different time intervals.
- the data represent the mean ⁇ SEM of expression levels per group.
- Fig. 22 illustrates the effect of the treatment on total fecal bile acid levels.
- the data represent the mean ⁇ SEM of expression levels per group.
- Fig. 23 illustrates the number of adenoma (a) and Gastrointestinal Intraepithelial Neoplasias (b) for three groups: Control - gavaged empty APA microcapsules + 0.85% saline, Treatment 1 - gavaged L. acidophilus bacterial cells in APA microcapsules + 2% M. F. yogurt and Treatment 2 - gavaged L. acidophilus bacterial cells in APA microcapsules + 0.85% saline found in the large intestines. Data represent the mean ⁇ SEM per group.
- Fig. 24 illustrates the number of adenoma (a) and Gastrointestinal Intraepithelial Neoplasias (b) for three groups: Control - gavaged empty APA microcapsules + 0.85% saline, Treatment 1 - gavaged
- FIG. 25 illustrates histological sections showing intestinal changes in C57BL/6J- ⁇ pc M ⁇ n/+ mice.
- Fig. 25 (a) consists of a representative tumor of the colon found in a control untreated mouse shows pedunculated (polypoid) adenoma with high grade of dysplasia. Original magnification 4OX.
- Fig. 25 (b) consists of gastrointestinal intraepithelial neoplasia (microadenoma) of the small intestine found in a mouse gavaged with L acidophilus bacterial cells in APA microcapsules + 2% M. F. yogurt.
- FIG. 25 (c) consists of papillary Adenoma in small intestine, sessile with low grade of dysplasia (arrows) (Sessile adenomatous polyp) found in a mouse gavaged with L. acidophilus bacterial cells in APA microcapsules + 2% M. F. yogurt 0.85% saline.
- Fig. 25 (d) consists of broad-based adenoma of small intestine found in a mouse gavaged with L. acidophilus bacterial cells in APA microcapsules + 0.85% saline.
- the bacteria to be encapsulated is chosen from any Lactobacilli and any Bifidobacterium.
- Known such bacteria include L. casei, L. acidophilus, L. plantarum, L. fermentum, L. brevis, L. jensenii, L. crispatus, L. rhamnosus, B. longum and B. breve.
- the preferred bacteria used in accordance with the present invention are L. acidophilus, L. casei and Bifidobacterium bifidus.
- the microencapsulated bacteria are coated with a 0.1% PLL and 0.1% alginate solution. Accordingly, the present invention is effective with any microcapsules.
- the encapsulated live bacteria may be suspended in a probiotic acceptable carrier.
- a probiotic acceptable carrier is chosen, without limitation, from a food supplement or food. More preferable, it can be chosen from yogurt, ice cream, cheese, chocolate, nutritional bars, cereal, milk, infant formulation, fruit juices.
- dairy products specially youghurt its composition such as nutrients (viamines, metal ions, cofactors, proteins, fat contents, sugars, etc) will provide a further protection for the encapsulated live bacterial cells from the gastric fluids and other gastrointestinal environments.
- L. acidophilus (ATCC 314) cells were inoculated in 10OmL of
- MRS broth The bacteria were then cultured in MRS Broth at 37 0 C in a Professional Sanyo MCO-18M Multi-Gas Incubator. Cultures were grown for 24 hours and centrifuged at 300Ox g for 15 minutes at 37 0 C. The media was decanted; the cells were suspended in 10OmL of fresh MRS media and incubated for an additional 20 hours at 37 0 C. After growth was performed, the resulting cell wet weights were noted. Anaerobic jars and gas generating kits (Atmosphere Generation System AnaeroGenTM; Oxoid Ltd., Hampshire, England) were used for creating anaerobic conditions. Microcapsules containing live bacteria were homogenized manually to dilution and plating. Cell count was determined by anaerobic spread plate on MRS agar after 48 hours and was kept constant at 10 10 cfu/g throughout the experiment.
- APA capsules were prepared aseptically using an lnotech EncapsulatorTM IER-20 (lnotech Biosystems Intl. Inc. Switzerland) with a nozzle size of 300 ⁇ m at a frequency of 1160 Hz, 26.9 syringe pump speed and a voltage of 1.000 kV using a 60 ml syringe.
- 60ml of 1.5% (w/v) sodium alginate (low viscosity) was mixed with 3g of harvested bacterial cells (approximate cell load 10 10 cfu/g) by centrifuging twice at 300Ox g for 15 minutes with a single wash in 0.85% physiological solution between centrifugations.
- microcapsules were hardened in 0.1 M calcium chloride solution for 30 minutes, the optimal hardening time (Chandramouli.V. et al., (2004), Journal of microbiological methods 56:27-35).
- the resulting microcapsules were coated with 0.1 % PLL and 0.1% alginate solution in the same manner as in preparation of APA microcapsules mentioned below.
- These APA microcapsules loaded with bacterial cells were washed twice with 0.85% physiological solution and stored at 4°C until further use.
- APA capsules were prepared according to the standard protocol (Sun.A.M.F. et al., (1987), Crc Critical Reviews in Therapeutic Drug Carrier Systems 4:1-12) but with several modifications.
- spherical (580 ⁇ 26 ⁇ m) APA membrane microcapsules were subjected to in vitro mechanical shaking incubation (150 rpm) in MRS broth for 76 hours in a Lab Line Environ Shaker at 37°C.
- Empty and L. acidophilus loaded APA microcapsules were also exposed to various test fluids: simulated gastric fluid (SGF) and simulated intestinal fluids (SIF), for 3, 12 and 24 hours at 150 rpm shaking and at 37 0 C. Samples were withdrawn and visually analyzed for physical damage using an optical light microscope. Evaluation of microencapsulated live L. acidophilus cells viability in yogurt.
- SGF gastric fluid
- SIF simulated intestinal fluids
- the test samples contained 1Og of APA microcapsules loaded with L acidophilus cells and 1Og of empty APA microcapsules, each immersed in 100 mL of yogurt.
- Two control samples were set up as follows: 1g of APA microcapsules loaded with L. acidophilus cells in 1OmL of (0.85%, pH 7.2) physiological solution and 1g of empty APA microcapsules in 1OmL of (0.85%, pH 7.2) physiological solution.
- the microcapsules were filled into 20OmL polyethylene wide mouth dilution tubes in which the bottoms were cut out and replaced with mesh net (200 microns) and placed into 2L polyethylene containers.
- microcapsules were trapped to ensure a proper separation from the bacterial cultures of L. acidophilus cells already present in the yogurt when purchased. Before microcapsules were analyzed for the viability of the encapsulated bacterial cells they were washed in (0.85%, pH 7.2) physiological solution 10 times to ensure complete removal of yogurt particulates. All the samples were stored at 4 0 C and exposed to shaking at 100 rpm. Sampling was performed on a weekly basis and photomicrographs were taken at the same time. Microcapsule leakage study
- Microcapsule membrane leakage was monitored on a weekly basis by plating the 0.85% physiological solution in which the APA microcapsules loaded with L. acidophilus cells were stored for a period of 4 weeks at 4 0 C. Evaluation of the survival of microencapsulated L. acidophilus cells in different pH environments with and without addition of yogurt
- pH 2 of 0.2M KCI buffer pH 3 of 0.1 M KHP buffer and pH 4 of 1.0M KHP buffer
- pH 6 of 0.1 M KH 2 PO 4 buffer pH 8 of
- TRIS buffer 0.1 M TRIS buffer.
- 40OmL of each buffer was autoclaved and cooled to room temperature and 10OmL of yogurt was added.
- the bottoms of 15m L polyethylene tubes were cut out and replaced with a 200 ⁇ m nylon mesh.
- These modified tubes were then filled up with 10g of L. acidophilus loaded APA microcapsules. Samples were stored in anaerobic conditions at 37 0 C in glass bottles. Sampling under sterile conditions was performed during the following time intervals: 5, 10, 15, 30, 60, 120, 180, 360, 1080, 2520 and 4320 minutes.
- each of the five reactor vessels represents distinct parts of the human Gl tract in the following order: the stomach, the small intestine, the ascending colon, the transverse colon and the descending colon.
- a simulated gastric fluid SGF
- a carbohydrate-based diet was composed of arabinogalactan 1.0 g/L, pectin 2.0 g/L, xylan 1.0 g/L, starch 3.0 g/L, glucose 0.4 g/L, yeast extract 3.0 g/L, peptone 1.0 g/L, mucin 4.0 g/L, cystein 0.5 g/L and pH was adjusted with 0.2N HCI was used.
- 1.5g of APA microcapsules loaded with L. acidophilus was added to 1OmL of SGF fluid and 5mL of yogurt.
- the control sample was SGF fluid.
- the study compared the survival of free L acidophilus in SGF fluid only and APA microcapsules loaded with L. acidophilus in SGF fluid but in the absence of yogurt.
- Fig. 1 displays photomicrographs of freshly encapsulated empty capsules and capsules loaded with L. acidophilus cells. In the photomicrographs, under light microscopy, the capsules reveal their homogeneity, spherical shape and similar size. The empty APA microcapsules appear translucent and L. acidophilus loaded APA microcapsules are opaque owing to a dense load of L. acidophilus cells. Each subsequent microencapsulation yielded a similar bacterial cell load, kept constant at 10 10 cfu/g.
- the microcapsules need to be resistant to mechanical stress.
- Fig. 2 depicts photomicrographs of freshly prepared empty APA microcapsules as well as those loaded with L. acidophilus cells after an incubation period of 76 hours.
- a study of the APA capsule morphology revealed that no structural damage was visually noticeable; and therefore they were considered suitable for further testing.
- APA microcapsule stability was carried out by exposing the APA microcapsules containing live LAB cells to simulated gastric fluid (SGF) solution (pH 1.98) at 37 0 C for 3, 12 and 24 hours with 150 rpm mechanical shaking. Microscopic assessment was performed to evaluate microcapsule integrity. Results show that APA microcapsules were sturdy after exposure and remained intact in SGF for up to 24 hours at pH 1.98 and with 150 rpm shaking (Figs. 3a, 3b and 3c). We also evaluated the APA microcapsule stability in simulated intestinal fluid (SIF) at 37 0 C and with 150 rpm mechanical shaking. The APA membrane was found to have remained intact and microcapsules shown to preserve their original spherical shape after 24 hours. APA microcapsules were seen to swell after 3 hours.
- SGF gastric fluid
- FIG. 4 shows the percentage of undamaged APA microcapsules as a function of time; 100% of the APA microcapsules were unchanged after exposure to SGF for 3 hours and SIF for 3 hours. Moreover, no damage was found to occur to the APA microcapsules after treatment for 3 hours in SGF and 12 hours in SIF.
- FIG. 5 shows photomicrographs of APA microcapsules loaded with L. acidophilus cells.
- Pictures Y1 to Y4 were taken weekly over a period of 4 weeks and show APA microcapsules stored in 2% M. F. plain yogurt exposed to mechanical shaking at 100 rpm at 4 0 C.
- Photomicrographs P1 to P4 show APA microcapsules stored in 0.85% physiological solution, over 4 weeks, stored under similar conditions of 4 0 C and shaking at 100 rpm.
- This 4-week study revealed that APA microcapsules loaded with L acidophilus cells preserve their shape and integrity over time. The survival of encapsulated L. acidophilus over the 4-week study is shown in Fig.
- APA microcapsules The capacity of APA microcapsules to retain its cell load was measured over 4 weeks.
- APA microcapsules loaded with L. acidophilus cells were stored in 0.85% physiological solution at 4 0 C and the supernatant from the medium was plated weekly.
- Fig. 6(B) shows the percentage survival of live L. acidophilus cells in 0.85% physiological solution over time. A steady increase in the bacterial count was found over 4-weeks. After the fourth week, it was found that 2.21 log cfu/g of L. acidophilus cells had seeped from the APA microcapsules into the storage medium. Survival of microencapsulated L. acidophilus cells in different pH environments with and without supplementation with yogurt
- a novel yogurt formulation for oral bacterial delivery using microencapsulation technology was designed in accordance with the present invention.
- the probiotic bacterium L. acidophilus was encapsulated within APA microcapsule.
- Any matrix for cell immobilization ideally should provide physical support and uniform distribution of immobilized cells where the transport gradient of nutrients toward and waste products away is balanced and necrosis is prevented.
- the most common type of membrane used for cell therapy is the single alginate based polymer membrane.
- Various other substances are also being used for encapsulation such as various proteins, polyhemoglobin, and lipids. From a variety of naturally derived membrane materials (e.g.
- alginate and poly-L-lysine capsule was selected because alginate is an accepted, generally regarded as safe (GRAS) non-toxic food additive and poly-L-lysine is a natural, safe poly-aminoacid.
- GRAS safe
- Calcium ions provide cross- linking with sodium alginate through ionotropic gelation.
- the PLL coating is shown to provide immunoisolation.
- the outer alginate layer coating the microcapsules provides better acid stability and improved mechanical strength. In doing so, the biocompatibility of the multilayer structure is optimized.
- the molecular weight cut off (MWCO) of the resultant APA membrane was determined to be 60-70 KD, which provides a useful selectivity limit. This would allow the polymer membrane to protect encapsulated materials from harsh external environments, while at the same time allowing for the metabolism of selected solutes capable of passing in and out of the microcapsule.
- microencapsulation technique used yields spherical alginate microcapsules that have a narrow size distribution and retain L acidophilus bacterial cultures (Fig. 1).
- microcapsules must demonstrate good mechanical resistance and results show that the APA microcapsules maintain their integrity even after prolonged mechanical agitation (Fig. 2).
- the APA microcapsules demonstrated excellent resistance to simulated intestinal and gastric fluids and only underwent a slight swelling when exposed to SGF for 3 hours and SIF for 24 hours at 37 0 C with agitation at 150rpm (Fig. 3).
- 97% of the microcapsules remain intact after being exposed for 3 hours to SGF and 24 hours to SIF at 150rpm and 37 0 C.
- Microencapsulated L acidophilus cells were later stored in 2% M. F. yogurt and physiological solution (0.85%, pH 7.2) over 4 weeks. The viability of live L acidophilus in microcapsules and their morphology was monitored. From the photomicrographs, taken weekly, it is seen that the shape of the microcapsules is well preserved and when compared to microcapsules stored in physiological solution, neither the 2% M. F. yogurt nor shaking at 100 rpm alters their integrity or appearance (Fig. 5). Both media, differing significantly in their viscosities (2% M. F. yogurt and 0.85% physiological solution) serve equally well as storage media for APA microcapsules. This implies superior resistance to mechanicalshear and a tolerance to the various components of the simulated Gl fluids. An initial cell load of 10 7 cfu/g is recommended by National
- Yogurt Association for yogurt to be called a probiotic These high numbers have been suggested to compensate for the possible loss in the numbers of probiotic organisms during passage through the stomach and intestine.
- a cell load of 10 10 (cfu/g) was used. Higher initial load was selected to ensure delivery of a greater number of live bacteria to target sites.
- 7.53 log (cfu/g) of the encapsulated bacteria remained alive with 100 rpm shaking at 4 0 C (Fig. 6(A)). This duration was chosen as it approximates the length of time yogurt can be stored in a refrigerator after purchase.
- the microcapsule permeability study performed over 4 weeks shows a steady release of the bacteria into the physiological storage solution (0.85% NaCI, pH 7.2). The cumulative count after 4 weeks was found to be approximately 2.21 log (cfu/g) of the encapsulated live bacteria (Fig. 6(B)). Thus the microcapsules seem to retain bacteria adequately.
- Fig. 8 shows the survival of encapsulated and free bacteria using a model of a human stomach at 37 0 C over two hours, the time it takes food to pass through the stomach. After two hours, 7.10 log (cfu/g) of microencapsulated L acidophilus cells in the presence of SGF and 2% M. F. yogurt were still alive, while only 5.51 log (cfu/g) of free L acidophilus cells were found to be viable in presence of SGF. In addition, 6.66 log (cfu/g) of microencapsulated L. acidophilus cells in SGF fluid without yogurt were reported alive.
- yogurt might posses some additional protective properties.
- the protective effect of yogurt on bacterial cells has been attributed to several factors. These include the strains of inherent probiotic bacteria, pH, hydrogen peroxide, storage atmosphere, concentration of metabolites such as lactic acid and acetic acids, dissolved oxygen, and buffers such as whey proteins (Dave, R. I. et al., (1997), International Dairy Journal 7:31-41; Kailasapathy.K et al., (1997), Australian Journal of Dairy Technology 52:28-35).
- the difference in the survival of microencapsulated L. acidophilus cells in the presence and absence of 2% M. F. yogurt indicates that yogurt may further help protect microencapsulated L. acidophilus cells.
- Results show that APA microcapsules display good mechanical stability in storage solutions.
- This study also demonstrates the protective properties of the APA membrane in low pH conditions, and in simulated gastric fluid. This indicates that ingested microcapsules may be capable of surviving the passage through the stomach and reaching the target sites further in the Gl tract with an adequate cell load which can be further enhanced by using yogurt.
- yogurt containing APA microencapsulated L acidophilus may represent a significant improvement over ordinary yogurt in the delivery of probiotic bacterial cells for possible treatment of Gl tract related diseases such as in colon cancer. Further studies, however, are required to substantiate this hypothesis, in particular in vivo confirmation of their effectiveness in experimental animal models.
- Bacteria cultures, propagation and enumeration L. acidophilus (ATCC 314) cells were inoculated in 10OmL of
- Alginate-Chitosan (AC) microcapsules were prepared aseptically using an lnotech Encapsulate*® IER-20 (Inotech Biosystems Intl. Inc. Switzerland) in a Microzone Biological Containment Hood (Microzone Corporation ON, Canada). The following parameters for microencapsulation were used: a nozzle size of 300 ⁇ m at a frequency of 918 Hz, 24 syringe pump speed and a voltage of >1.000 kV using a 60 ml syringe. All membrane components were filter sterilized through a 0.22 ⁇ m Sterivex-GS filter prior to use.
- the pellet of wet cells was centrifuged twice at 300Ox g for 10 minutes, weighted and kept constant at 1.7g, suspended in 0.85% saline, pooled and slowly added to a gently stirred 6OmL sterile 1.5% (w/v) sodium alginate (low viscosity) solution.
- the approximate cell load was kept constant at 10 10 cfu/g.
- Formed microcapsules were hardened in 0.1 M calcium chloride solution for 30 minutes, the optimal hardening time.
- the resulting microcapsules were coated with 0.5%, 0.25% and 0.1% chitosan 10 solution dissolved in dilute acetic acid at a pH of 5.3 for 30 min. These AC microcapsules loaded with bacterial cells were washed twice with 0.85% physiological solution and stored at 4°C until further use.
- AC capsules were prepared according to the standard protocol with several modifications. Briefly, Ca-alginate beads were exposed to chitosan solution (0.5% w/v) for 30 minutes, washed twice with physiological solution (0.85%w/v, pH 7.2). The resulting AC microcapsules were washed twice with 0.85% physiological solution and stored at 4°C until used.
- FIG. 9 displays photomicrographs of freshly encapsulated empty capsules and capsules loaded with L. acidophilus cells of 550 ⁇ 26 ⁇ m in size and magnification of 2.5x using light microscopy. Microcapsules exhibit homogeneous spherical shape. Empty capsules are transparent and capsules loaded with bacterial cells are opaque due to high concentration. Each subsequent microencapsulation yielded a similar bacterial cell load, kept constant at 10 10 cfu/mL.
- Fig. (10a) displays empty AC microcapsules
- Fig. (10c) same capsules after 76 hours of incubation in MRS broth exposed to mechanical shaking of 150rpm at 37 0 C. It can be observed that the physical morphology of the capsules after being subjected to an intense mechanical stress does not impact capsules integrity or their shape. Upon close examination no damage was noted. Therefore, the capsules preserve their robustness while being exposed to harsh conditions.
- microcapsules containing bacterial cells were subjected to various fluids found in SHIME (Fig. 11). In addition, all the samples were exposed to mechanical shaking of 150rpm at 37 0 C. All the photomicrographs were taken using magnification of 6.3x. Upon close examination no physical damage was observed and the capsules remained intact.
- Fig. 14 displays survival of AC encapsulated and free bacterial cells obtained by exposure to simulated intestinal fluid conditions.
- the viability of encapsulated L. acidophilus and free cells in the presence and absence of 2% M. F. yogurt was tested over 6 hours.
- Crucial time points at 120 minutes - the stomach's approximate retention time, and at 360 minutes - the small intestine's retention time showed 8.05, 7.47, 6.54 and 7.96, 7.09 and 6.24 log cfu/mL, respectively.
- Figure 16 depicts a study performed during 4 weeks where different chitosan 10 concentrations were used, namely 0.5%, 0.25% and 0.1 %. Microcapsules coated with these polymers were stored in 0.85% physiological solution and kept at 4 0 C. Free L. acidophilus cells in 0.85% physiological solution were set up as a control at 4 0 C. A constant drop of bacterial survival was observed over the 4-week study (Fig. 16). The highest survival rate was noticed for chitosan 10 at 0.5% concentration, 9.11 log cfu/mL and the lowest for chitosan 10 at 0.1% concentration - 8.56 log cfu/mL. Free bacterial cells have reached complete downfall at the second week.
- Figure 18 shows the survival of encapsulated live L acidophilus cells in buffers of pH 2, 3, 4, 6 and 8 supplemented with 2%M.F. yogurt. Contrary to the previous results, cells exhibited the highest survival at pH 8, 10.34 log cfu/mL, and lowest at pH2 of 7.48 log cfu/mL. Moreover, at pH 6 cells reached 10.07 log cfu/mL, at pH 4, 7.56 log cfu/mL and 7.82 log cfu/mL at pH 3. This is consistent with the lactic acid bacteria as they produce lactic acid as a result of carbohydrate fermentation and their growth lowers both the carbohydrate content of the media that they ferment, and the pH due to lactic acid production.
- Lactobacillus acidophilus (ATCC 314) cells were cultivated and serially propagated three times in the MRS medium before experimental use. Incubations were performed at 37°C in a Professional Sanyo MCO-18M Multi- Gas Incubator in anaerobic conditions (1-2% CO2, Atmosphere Generation System AnaeroGenTM; Oxoid Ltd., Hampshire, England). Bacteria to be encapsulated were isolated after 20 hours of the 3 rd passage. Microencapsulation method The bacterial strains were microencapsulated into Alginate-Poly-L- Lysine-Alginate (APA) membranes. All membrane components were filter sterilized through a 0.22 ⁇ m Sterivex-GS filter prior to use.
- APA Alginate-Poly-L- Lysine-Alginate
- APA microcapsules were prepared aseptically using an lnotech Encapsulator® IER-20 (lnotech Biosystems Intl. Inc. Switzerland). Freshly prepared microcapsules were washed twice with 0.85% saline and stored at 4°C. Parameters for microencapsulation were as follows:
- APA microcapsules loaded with L. acidophilus bacterial cells were blended with Liberty plain yogurt 2% M. F. and 0.85% saline in the proportions of 1.5:0.5, respectively.
- Empty APA microcapsules were suspended in 0.85% saline using same formulation.
- mice are heterozygous for ApcM ' m+ ⁇ Miri), a germ-line truncating mutation at codon 850 of the Ape gene and spontaneously develop pretumoric numerous intestinal neoplasms 41 .
- Ape (1vlin/+) mouse is a popular animal model for studies on human colorectal cancer 42 . It is used to study the effects of genetics, diet, or chemical compounds on the incidence and development of intestinal precancerous lesions, the adenomas 43 .
- the germ-line mutations in the APC gene lead to FAP, but inactivation of APC is also found in 80% of sporadic colorectal cancers 44 .
- mice 45 Male heterozygous C57BL/6J-Apc M ⁇ n/+ mice 45 , weighing 20-25 g, were obtained from The Jackson Laboratory (Bar Harbor, ME). The animals kept in the Duff Medical Building Animal Care Facility on a 12-hour light-dark cycle and controlled humidity and temperature. They were allowed sterile water and the laboratory rodent diet 5001 from Purina Land O'Lakes ad libitum. Animals overall health was monitored daily.
- mice 7 or 8 weeks old were used.
- the life span of these mice is 119 ⁇
- mice 31 days 46 .
- the mice were separated into three experimental groups: 1) Control - animals were gavaged empty APA microcapsules suspended in
- mice were ranked and randomly block assigned to the aforementioned groups. There were 11 animals per group. Animals were weighed individually every week; the saphenous vein was bleed every 4 weeks and feces samples were collected at specific intervals throughout the experiment. There were 3 end points at weeks 8, 10 and 12 of treatment at which 9, 9 and 15 animals were sacrificed, respectively.
- IL-6 Interleukin-6 Determination, lnterleukin-6 (IL-6) is a cytokine secreted by diverse cell types under homeostatic and inflammatory conditions
- Interleukin (IL)-6 mRNA expression in general is low in normal, adenomatous and cancerious human colon mucosa; except in rather undifferentiated lesions, in which IL-6 is over expressed.
- IL-6 has been shown to be associated with cancer development. However, its role in gastric cancer has never been investigated. For this, blood samples were collected every 4 weeks into heperinized tubes which after blood collection were centrifuged at 5000 xg for 20 minutes to yield plasma which was used in further testing. The release of IL-6 from plasma samples into the culture medium was quantified by enzyme-linked mouse immunosorbent assay (ELISA, Biosource, Invitrogen, USA) according to manufacturer's instructions.
- ELISA enzyme-linked mouse immunosorbent assay
- Fecal Bile Acids Determination Feces were collected at specific intervals throughout the experiment and the analysis was performed per group per cage. Total fecal bile acids were determined as previously described 48 , 49 with the following modifications. 25uL of sample were used to determine total bile acid concentration enzymatically as previously described 50 using a commercially available kit (Sigma Diagnostic Bile Acids 450A, Sigma Diagnostics, St. Louis, Missouri, USA).
- mice Adenoma Enumeration, Classification and Histopathology.
- the mice were euthanised by CO 2 asphyxiation, and the small, large intestine and cecum were excised.
- the intestines were infused with 10% Phosphate Buffered Formalin (PBF) after which the Swiss Roll was performed by which they were placed in cassettes and immersed in 10% PBF as a fixative.
- PPF Phosphate Buffered Formalin
- Five-um paraffin-embedded sections were stained with H&E for histological evaluation. Polyp scoring was performed by a blinded veterinary pathologist to the treatment.
- GI intraepithelial neoplasia GIN
- adenoma >1mm
- Fig. 19 displays photomicrographs of freshly encapsulated loaded with L. acidophilus bacterial cells capsules obtained using a light microscopy magnification of 6.3x. They were 433 ⁇ 67 ⁇ m in size. Using optimal settings each microencapsulation yielded a fixed bacterial cell load, kept constant in a range of 10 10 cfu/ml_. After acclimatization period of one week, the animals were randomly block assigned into 3 groups, each composed of 11 animals. Body weights were taken down on weekly basis. (Fig. 20). There was a steady drop of body weight in control group animals, from 24.6 ⁇ 0.48 to 22 ⁇ 1.47 grams over 12 weeks whereas the body weights remained stable in both treatment groups. Interleukin- 6 level was determined in experimental animals.
- SENSA test results in a blue-colored compound which occurs when guaiac is oxidized by hydrogen peroxide.
- the abnormal bleeding is associated with gastrointestinal disorders and can be qualitatively detected with a higher sensitivity than standard guaiac tests.
- Adenoma reduction in the treated animals Classification and Histopathology.
- adenomas both with low and high grade dysplasia and gastrointestinal intraepithelial neoplasias (GIN) were scored for each animal group in small and large intestines. The numbers were averaged per animal in a given group. In the large intestines, there was 0.8 of adenomas found in control group versus 0.4 and 0.7 in treatment 1 and 2 groups, respectively (Fig. 23a). In the small intestines, there were 28 of adenomas found in control group versus 13 and 18 in treatment 1 and 2 groups, respectively (Fig. 24a). In the large intestines, there were 0.3 GIN's found in control group versus 0.2 and 0.1 in treatment 1 and 2 groups, respectively ( Figure 23b). In the small intestines, there were 8 GIN's found in control group versus 4 and 6 in treatment 1 and 2 groups, respectively (Fig. 24b).
- IL-6 secretion of IL-6 is strongly associated with the pathogenesis of IBD, and overproduction of IL-6 by intestinal epithelial cells is thought to play a part in the pathogenesis of IBD.
- IL-6 and TNFa can initiate the innate immune response by inducing the acute phase of inflammation.
- IL-6 also appears to be involved in malignant transformation, tumor progression and tumor-associated cachexia, as reported in studies on Kaposi's sarcoma, multiple myeloma, renal cell carcinoma, prostate cancer, ovarian cancer and breast cancer.
- the presence of blood in feces is one of many symptoms that may indicate the presence of polyps in the colon or rectum, or cancer.
- the Hemoccult SENSA test was performed at the beginning and the end of treatment. The rectal bleeding was observed in animals on arrival and the test was repeated at the end of experiment to verify whether the treatment has an effect to lower the amount of blood detected.
- This qualitative test detected the presence of blood in the feces in all animal cages at the end of the treatment which does not reveal any significant changes within the groups. It is known that bile acids contribute to colonic carcinogenesis by disturbing the fine balance between proliferation, differentiation, and apoptosis in colonic epithelial cells.
- Bile acids in the feces act as a promoter of colon cancer, in particular deoxycholic acid (DCA), which is one kind of the secondary bile acid.
- DCA/cholic acid (CA) ratio in feces is also said to have a diagnostic significance in colon cancer.
- adenoma Most of the adenoma found were sessile/broad-based and were composed of papillary projections of lamina intestinal covered by an epithelium. There was no adenoma or lesions found in removed ceca. The greatest loss in mucin secretion was displayed in severely dysplastic glands of control group animals sacrificed at 12 th week of the experiment. The glands were closely packed with one another and their structural atypia, e.g., "back to back" arrangement became more prominent. Nuclei were plump but still uniform and smaller than those in carcinomatous glands. Cytological abnormalities detected included cellular and nuclear pleiomorphism and loss of polarity.
- microencapsulated probiotic bacteria in yogurt formulation exert promising action on polyp progression by delaying the intestinal inflammation and maintaining the constant body weight of Min mice.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to an oral formulation comprising a microcapsule containing bacteria and a fermented milk carrier. There is also provided a method of medical treatment of an inflammatory gastrointestinal disease or disorder in a subject in need thereof, comprising detecting the presence of inflammatory gastrointestinal disease or disorder in the subject, wherein if inflammatory gastrointestinal disease or disorder is detected, then administering the formulation of the present invention to the subject.
Description
TITLE: Fermented milk product and use thereof
BACKGROUND OF THE INVENTION
(a) Field of the Invention The present invention relates to a novel method for encapsulating live bacteria; an encapsulated live bacteria; an oral formulation for probiotic therapy and method of treatment thereof.
(b) Description of Prior Art
A well balanced gut microflora is known to contribute to the maintenance of a healthy intestinal mucosa. The density of gastrointestinal (Gl) microflora increases from the stomach to the large intestine reaching 1010 - 1012 cfu/g in the colon. One of the most important groups of bacteria for intestinal health is lactic acid bacteria (LAB) (Adolfsson, O. et al., (2004), American Journal of Clinical Nutrition 80:245-256). LAB are considered probiotic; live microorganisms that remain in the Gl tract to benefit the host (Adolfsson, O. et al., (2004), American Journal of Clinical Nutrition 80:245- 256; Roberfroid, 2000). Although their mechanism of action is not known, it is believed that LAB, like other probiotic microorganisms, compete and suppress the growth of undesirable microorganisms in the colon and intestines leading to the stabilization of the digestive system (Adhikari.K. et al., (2000), Journal of Dairy Science 83:1946-1951).
There are several reports that probiotic yogurt has significant clinical benefits (Donaldson, M. S., (2004), Nutrition Journal 3:19). It is estimated that a decrease of at least 60-70 percent in breast, colorectal, and prostate cancers and 40-50 percent in lung cancer would occur when a diet is complied with (according to the anti-cancer diet guidelines) which includes probiotic yogurt products. In order to be labeled probiotic, yogurt must contain a cell load of at least 107 cfu/g at the time of manufacture (Chandan.R.C. et al., (1993), Ed Hui, Y H, VCH Publishers, lnc , New York1-56). However, it has been found that this level of live bacterial cells in probiotic yogurt is not adequate to provide the maximum benefit, especially considering that many
bacteria do not survive storage (Donaldson,M.S., (2004), Nutrition Journal 3:19), (Dave.R.I. et al., (1998), Journal of Dairy Science 81 :2804-2816), (Shah, N. P., et al., (1995), International Dairy Journal 5:515-521) or passage through the stomach. Therefore several attempts have been made to deliver a greater number of live bacterial cells. One strategy to deliver more live bacteria to the intestines is bioencapsulation. This technology has developed over the last 20 years, (Orive,G. et al., (2003b), International Journal of Pharmaceutics 259:57-68; Prakash,S. et al., (1996b), Nature Medicine 2:883-887; Sun et al., 1987, ChangJ.M.S. et al., (1998), Molecular Medicine Today 4:221-227; Prakash.S. et al., (1998), Artificial Cells Blood Substitutes and Immobilization Biotechnology 26:35-51 ; Jones.M.L et al, (2004), Journal of Biomedicine and Biotechnology 1 :61-69). However, the use of this technology in probiotic yogurt formulation containing live bacteria has not yet been investigated. The transit of free bacteria through the gastrointestinal tract is often problematic because of low pH conditions, enzymatic digestion and very few probiotic cells finally reach their targeted site. The challenge here consist in producing a support allowing successful storage and transport of bacteria which could, if added to one's diet, constitute an alternative but effective treatment to various medical issues caused by an imbalance between desirable and undesirable microorganisms in the Gl microflora.
Therefore, it would be highly desirable to be provided with a novel method to encapsulate live bacteria and which would be safe for oral administration as a probiotic formulation to improve gastrointestinal microflora's condition.
SUMMARY OF THE INVENTION
Herein we report the potential of microcapsules as a platform for probiotic live bacterial cell oral delivery. In vitro data suggests that capsules containing live Lactobacillus acidophilus cells showed superior mechanical stability and demonstrated significantly higher bacterial cell survivals compared to free bacterial cells over a period of 4 weeks. Using an in vitro
simulation human stomach model, we monitored the survival rates of free and alginate-poly-L-lysine (PLL)-alginate (APA) membrane microencapsulated L. acidophilus cells at 370C over two hours, the approximate time it takes food to pass through the stomach. Results show that 7.10 log cfu/g of microencapsulated L. acidophilus cells were found alive compared to only 5.51 log cfu/g of free L. acidophilus cells in the presence of simulated gastric fluid (SGF) and 2% milk fat M. F. yogurt. In addition, data shows that only 6.66 log cfu/g of microencapsulated L. acidophilus cells survived in SGF fluid in the absence of yogurt. The high survival rates of encapsulated L. acidophilus cells strongly suggest the use of microcapsules and yogurt for probiotic bacterial cell delivery.
In accordance with the present invention there is provided an oral formulation to improve a patient gastrointestinal microflora, which comprises coated microcapsule containing bacteria in suspension in a probiotic acceptable carrier, wherein said coated microcapsule comprises an encapsulated bacteria in a semipermeable capsule coated with poly-L-Lysine (PLL) and alginate and is also resistant in gastrointestinal conditions.
The bacteria may be chosen from Lactobacilli cells, Bifidobacterium cells, Lactobacillus plantarum 80, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus Rhamnosus, Lactobacillus, more particularly from Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium, Lactobacillus plantarum 80, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus Rhamnosus, Lactobacillus GG.
In accordance with a preferred embodiment of the oral formulation of the present invention, the bacteria is live.
In accordance with another embodiment of the oral formulation of the present invention, the microcapsule is made of a material chosen from alginate-poly-L-Lysine-alginate (APA), alginate-chitosan (AC), alginate pectinate polylysine pectinate alginate (APPPA), alginate polyethylene glycol alginate (APEGA), alginate chitosan genipin alginate (ACGA).
In accordance with another embodiment of the oral formulation of the present invention, the probiotic acceptable carrier is at a substantially basic pH to further protect from gastrointestinal fluids.
In accordance with another embodiment of the oral formulation of the present invention, the probiotic acceptable carrier is chosen from a food supplement or food.
In accordance with another embodiment of the oral formulation of the present invention, the food carrier is chosen from yogurt, ice cream, cheese, chocolate, nutritional bars, cereal, milk, infant formulation, fruit juices. In accordance with the present invention there is provided a method for probiotic therapy of a patient for improving gastrointestinal microflora, which comprises orally administering the oral formulation of the present invention.
In accordance with another embodiment of the method of the present invention, the patient is suffering from a disease or disorder chosen from breast cancer, colorectal cancer, prostate cancer, lung cancer, urinary tract infections, yeast infections and inflammatory bowel diseases (IBD),
Crone's diseases (CD).
In accordance with another embodiment of the present invention, there is provided an oral formulation comprising: a microcapsule containing bacteria; and a fermented milk carrier.
The microcapsule may comprise a semipermeable capsule comprising poly-L-Lysine (PLL) and alginate and wherein the microcapsule is resistant to degradation in gastrointestinal conditions.
The bacteria may be Lactobacilli bacteria or Bifidobacterium bacteria. The Lactobacilli bacteria are selected from the group consisting of Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum 80, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus Rhamnosus,
In accordance with another embodiment of the present invention, there is provided a method for treatment or prevention of a disease or disorder in a subject in need thereof or for nutritional supplementation of a subject, comprising orally administering to the subject the oral formulation of the present invention.
In accordance with another embodiment of the present invention, there is provided the use of the oral formulation of the present invention for the preparation of a medicament for the treatment or prevention of a disease or disorder or for the preparation of a nutritional supplement. In accordance with another embodiment of the present invention, there is provided a fermented milk carrier i) for use as a prebiotic carrier in increasing the efficacy of microencapsulated bacteria in the treatment of a disease or disorder in a subject or ii) for preparation of a medicament for the treatment of a disease or disorder in a subject; wherein optionally the carrier is used in the oral formulation of the present invention.
The subject may be a mammal, optionally a human.
The disease or disorder includes a gastrointestinal disease or disorder.
The gastrointestinal disease or disorder includes an inflammation gastrointestinal disease or disorder such as Inflammatory Bowel Disease (IBD), Crohn's Disease, colitis, enteroinvasive colitis, C. difficile colitis, Ulcerative Colitis (UC), Inflammatory Bowel Syndrome (IBS), pouchitis, diverticulitis, gastroenteritis, colic, appendicitis, appendicitis, ascending colangitis, esophagitis, gastritis, or enteritis. The disease or disorder includes cancer, such as breast cancer, colorectal cancer, prostate cancer, lung cancer, colon cancer and inflammation-related colon cancer, including adenoma, carcinoma, leiomyosarcoma, carcinoid tumor, or squamus cell carcinoma.
Lactobacillus GG, Bifidobacterium infantis, Bifidobacterium breve, Bifidobacterium Iongum, Bifidobacterium bifidum.
The bacteria may be live.
The bacteria may be present in a range from 109 to 1012 colony forming units (CFU).
The microcapsule may comprise a material selected from the group consisting of alginate-poly-L-Lysine-alginate (APA), alginate-chitosan
(AC), alginate pectinate polylysine pectinate alginate (APPPA), alginate polyethylene glycol alginate (APEGA) and alginate chitosan genipin alginate (ACGA).
The fermented milk carrier may comprise a basic pH buffer and protects the bacteria and/or the microcapsule from gastrointestinal fluids. The basic pH buffer may be between pH 7-9.
The fermented milk carrier may comprise a food supplement or food, such as yogurt, cheese, milk, powdered milk, kefer or a fermented milk formulation.
The yogurt may be selected from the group consisting of plain yogurt, flavored yogurt, yogurt beverage, Dahi, Dadiah, Labneh, Bulgarian Yogurt, Tarator, Cacik, Lassi and Kefir. The yogurt may comprise 1-10 grams of microencapsulated bacteria per 100 grams of yogurt, optionally 5-10 grams of microencapsulated bacteria per 100 grams of yogurt, optionally 8-10 grams of microencapsulated bacteria per 100 grams of yogurt.
The yogurt may comprise 4.2 grams of harvested bacteria in 100 mL of 1.65% alginate solution.
The oral formulation of the present invention may be use in nutritional supplementation of a subject or for use in preventing or treating a disease or disorder in a subject.
The disease or disorder includes inflammation of tissue in bowel, colon, sigmoid colon, rectum, appendix, anus, esophagus, stomach, mouth, liver, billiary, tract or pancreas, including inflammation of colon.
The inflamed tissue or colon comprises increased interleukins and cytokines compared to non-inflamed tissue or colon, such as up- regulated inflammatory response and markers compared to non-inflamed tissue or colon, such as tumor necrosis factor-α [TNF-α], interleukin-1 [IL-1], IL-6, IL-12, and γ-interferon in macrophages.
The disease or disorder includes a urinary tract related disease or disorder.
The urinary tract related disease or disorder includes a urinary tract infection or a yeast infection.
In accordance with another embodiment of the present invention, there is provided a method of medical treatment of an inflammatory gastrointestinal disease or disorder in a subject in need thereof, comprising detecting the presence of inflammatory gastrointestinal disease or disorder in the subject, wherein if inflammatory gastrointestinal disease or disorder is detected, then administering the formulation of any one of claims 1 to 13 to the subject. The detecting step may comprise determining the presence of inflammatory gastrointestinal disease or disorder in the subject with a biopsy of the subject's tissue or a blood test of the subject, such as detection of: elevated C Reactive Protein (CRP), increased Erythrocyte Sedimentation Rate (ESR), elevated neutrophil count, elevated eosinophil count, elevated monocyte count, elevated white blood cell count (WBC), elevated immunoglobulin count or elevated IgA, compared to a subject not having inflammation.
In accordance with another embodiment of the present invention, there is provided a method of medical treatment of inflammation-
related colon cancer in a subject in need thereof, comprising detecting the presence of inflammation-related colon cancer in the subject, wherein if cancer is detected, next administering the formulation of the present invention. The detecting step may comprise determining the presence of cancer in the subject using fecal occult blood (FOB), visible protrusion adenomatous polyps from the mucosal surface, digital rectal exam, colonoscopy, sigmoidiscopy, abdominal series radiograph with contrast, double contrast enema abdominal radiograph or abdominal CT scan. The detecting step may comprise determining the presence of cancer in the subject with a blood test of the subject comprising detection of elevated carcinoembryonic antigen (CEA) compared to a subject not having cancer.
The detecting step may comprise determining the presence of cancer in the subject with a biopsy of the subject's tissue or a blood test of the subject, such as detection of: elevated C Reactive Protein (CRP), increased
Erythrocyte Sedimentation Rate (ESR), elevated neutrophil count, elevated eosinophil count, elevated monocyte count, elevated white blood cell count
(WBC), elevated immunoglobulin count or elevated IgA, compared to a subject not having cancer, such as adenoma or carcinoma.
In accordance with another embodiment of the present invention, there is provided an oral formulation for the treatment and/or prevention of a disease and/or disorder, which comprises coated microcapsule containing bacteria in suspension in a fermented milk probiotic acceptable carrier, wherein said coated microcapsule comprises encapsulated bacteria in a semipermeable capsule coated with poly-L-Lysine (PLL) and alginate and is also resistant in gastrointestinal conditions.
For the purpose of the present invention the following terms are defined below.
The expression "mechanically resistant" is referring to an intrinsic construction's capacity of a microcapsule which allows to maintain its original structure and shape against physical and/or mechanical stresses in a particular environment. The expression "gastrointestinal conditions" is referring to the various mechanical stresses of the gastrointestinal tract and to the different acidity levels of the gastrointestinal fluids which ingested substances undergo. BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 , left, illustrates freshly prepared empty APA microcapsules whereas Fig. 1 , right, illustrates freshly prepared APA microcapsules loaded with L. acidophilus cells.
Fig. 2 is a photomicrograph of four different stages of APA microcapsules. In photomicrograph (a), freshly prepared empty APA microcapsules are shown whereas in photomicrograph (b), they were loaded with L. acidophilus. Photomicrograph (c) is an illustration APA microcapsules loaded with L. acidophilus cells after 76 hours of incubation in MRS broth and 370 rpm in vitro shaking at 37°C.
Fig. 3 illustrates empty APA microcapsules exposed to shaking at 150 rpm at 37°C in three different conditions. In (a), the microcapsules were introduced in SGF (pH 1.98) for 3 hrs. In b), they were incorporated in
SGF (pH 1.98) for 12 hrs and in (c), they were incorporated in SGF (pH 1.98) for 3 hrs and in SIF (pH 6.5) for 24 hrs.
Fig. 4 is a graph of the mechanical stability of empty APA microcapsules at various exposure times in simulated gastric fluid (SGF) (pH 1.98) and simulated intestinal fluid (SIF) (pH 6.5) after shaking at 150 rpm at 370C.
Fig. 5 is a photomicrograph of various APA microcapsules loaded with L. acidophilus cells, exposed to mechanical shaking of 100 rpm at
40C and stored in various conditions. In Y1) storage was in 2% M. F. yogurt for 1 week. In P1), storage was in 0.85% physiological solution for 1 week. In Y2) storage was in 2% M. F. yogurt for 2 weeks. In P2) storage was in 0.85%
physiological solution for 2 weeks. In Y3) storage was in 2% M. F. yogurt for 3 weeks. In P3), storage was in 0.85% physiological solution for 3 weeks. In Y4) storage was in 2% M. F. yogurt for 4 weeks and in P4), storage was in 0.85% physiological solution for 4 weeks. Fig. 6 A) is a graph of the viability of live L. acidophilus cells in
2% M. F. yogurt during 4 weeks of mechanical shaking at 100 rpm at 4 0C. Fig. 6 B) is a graph illustrating the retention capacity of APA microcapsules. The number of viable L. acidophilus bacteria in the supernatant of storage media gives an indication of how many L acidophilus bacteria have leaked from the microcapsules. The APA microcapsules loaded with L. acidophilus cells were stored in 0.85% physiological solution for 4 weeks at 40C. No mechanical stress was applied.
Fig. 7 is a graph evaluating the survival of APA encapsulated L. acidophilus cells in pH 2, 3, 4, 6 and 8 in presence of 2% M. F. yogurt at 37°C.
Fig. 8 is a graph effectuating a comparison of the survival of APA encapsulated and free L. acidophilus cells in conditions simulating the stomach supplemented with 2% M. F. yogurt at 370C.
Fig. 9 displays photomicrographs of freshly encapsulated empty capsules and capsules loaded with L. acidophilus cells of 550±26 μm in size and magnification of 2.5x using light microscopy. . Left: Photomicrograph of freshly prepared empty AC microcapsules(size 550 ±26 μm, magnification: 2.5x). Right: Photomicrograph of freshly prepared AC microcapsules loaded with L. acidophilus cells. Fig. 10 shows three comparative photomicrographs of freshly prepared microcapsules. Figure 10. (a) Photomicrograph of freshly prepared empty AC microcapsules, (b) Photomicrograph of freshly prepared AC microcapsules loaded with L. acidophilus, (c) Photomicrograph of AC microcapsules loaded with L. acidophilus cells after 76 hours of incubation in MRS broth and 150 rpm in-vitro shaking at 370C (Magnification: 2.5x).
Fig. 11 displays three photomicrographs of AC microcapsules exposed to simulated gastrointestinal fluid (SGF) (pH1.98) for 3 hours (11a), to SGF for 12 hours (11b) and to simulated intestinal fluid (SIF) (pH6.5) for 24 hours. Figure 11. Photomicrographs of AC microcapsules loaded with L acidophilus cells exposed to shaking at 150 rpm at 370C: (a) in SGF (pH 1.98) for 3 hrs. (b) in SGF (pH 1.98) for 12 hrs. (c) in SGF (pH 1.98) for 3 hrs and in SIF (pH 6.5) for 24 hrs. (Magnification: 6.3x).
Fig. 12 further demonstrates physical property of exposed microcapsules to a combination of simulated fluids. Mechanical stability of AC microcapsules loaded with L. acidophilus cells at various exposure times in simulated gastric fluid (SGF) (pH 1.98) and simulated intestinal fluid (SIF) (pH
6.5) after shaking at 150 rpm at 370C.
Fig. 13 illustrates the survival of encapsulated bacterial cells in SGF with and without addition of 2% M. F. yogurt as well as the survival of free bacteria contained in the yogurt. Comparison of the survival of AC (chitosan 10) encapsulated and free L. acidophilus cells using Simulated Human Intestinal Microbial Ecosystem - conditions simulating the stomach supplemented with 2% M. F. yogurt at 370C.
Fig. 14 displays survival of AC encapsulated and free bacterial cells obtained by exposure to simulated intestinal fluid conditions.
Comparison of the survival of AC (chitosan 10) encapsulated and free L acidophilus cells using Simulated Human Intestinal Microbial Ecosystem - condition simulating the intestines supplemented with 2% M. F. yogurt at 370C.
Fig. 15 is a comparative study - survival of AC 10 encapsulated L acidophilus in presence and of 2% M. F. yogurt at 40C and mechanical shaking of 100 rpm.
Fig. 16 illustrates comparative study of microencapsulated L acidophilus bacterial cells viability in various chitosan concentrations and polymers (0.5%/K), 0.25%/K), 0.1 %/10) in 2% M. F. yogurt with free L. acidophilus bacterial cells in 0.85% saline during 4 weeks of mechanical shaking at 100 rpm at 40C.
Fig. 17 Viability of free L. acidophilus cells in 2%M.F. plain yogurt in buffers: pH2, pH3, pH4, pH6 and pH8.
Fig. 18 Survival of AC encapsulated live L acidophilus cells in buffers: pH2, pH3, pH4, pH6 and pH8 supplemented with 2%M.F. plain yogurt.
Fig. 19 is a photomicrograph of APA microcapsules loaded with Lactobacillus acidophilus bacterial cells at 77* magnification and (b) at 112χ magnification, (size 433um±67)
Fig. 20 illustrates the effect of the treatment on animal body weights in the Min mouse. Data represent the mean ± SEM per group.
Fig. 21 illustrates the changes in the expression levels of antiinflammatory interleukin-6 examined during treatment at different time intervals. The data represent the mean ± SEM of expression levels per group.
Fig. 22 illustrates the effect of the treatment on total fecal bile acid levels. The data represent the mean ± SEM of expression levels per group.
Fig. 23 illustrates the number of adenoma (a) and Gastrointestinal Intraepithelial Neoplasias (b) for three groups: Control - gavaged empty APA microcapsules + 0.85% saline, Treatment 1 - gavaged L. acidophilus bacterial cells in APA microcapsules + 2% M. F. yogurt and Treatment 2 - gavaged L. acidophilus bacterial cells in APA microcapsules + 0.85% saline found in the large intestines. Data represent the mean ± SEM per group.
Fig. 24 illustrates the number of adenoma (a) and Gastrointestinal Intraepithelial Neoplasias (b) for three groups: Control - gavaged empty APA microcapsules + 0.85% saline, Treatment 1 - gavaged
L. acidophilus bacterial cells in APA microcapsules + 2% M. F. yogurt and
Treatment 2 - gavaged L acidophilus bacterial cells in APA microcapsules +
0.85% saline found in the small intestines. Data represent the mean ± SEM per group.
Fig. 25 illustrates histological sections showing intestinal changes in C57BL/6J-ΛpcMιn/+ mice. Fig. 25 (a) consists of a representative tumor of the colon found in a control untreated mouse shows pedunculated (polypoid) adenoma with high grade of dysplasia. Original magnification 4OX. Fig. 25 (b) consists of gastrointestinal intraepithelial neoplasia (microadenoma) of the small intestine found in a mouse gavaged with L acidophilus bacterial cells in APA microcapsules + 2% M. F. yogurt. Note the increased Nuclear / Cytoplasmic ratio, the nuclear crowding and the hyperchromasia of these glands (arrow). Original magnification 100X. Fig. 25 (c) consists of papillary Adenoma in small intestine, sessile with low grade of dysplasia (arrows) (Sessile adenomatous polyp) found in a mouse gavaged with L. acidophilus bacterial cells in APA microcapsules + 2% M. F. yogurt 0.85% saline. Original magnification 100X. Fig. 25 (d) consists of broad-based adenoma of small intestine found in a mouse gavaged with L. acidophilus bacterial cells in APA microcapsules + 0.85% saline. Original magnification 100X. All tissues were stained with hematoxylin eosin. DETAILED DESCRIPTION OF THE INVENTION
In accordance with one embodiment of the present invention, the bacteria to be encapsulated is chosen from any Lactobacilli and any Bifidobacterium. Known such bacteria include L. casei, L. acidophilus, L. plantarum, L. fermentum, L. brevis, L. jensenii, L. crispatus, L. rhamnosus, B. longum and B. breve. The preferred bacteria used in accordance with the present invention are L. acidophilus, L. casei and Bifidobacterium bifidus.
In accordance with another embodiment of the present invention, the microencapsulated bacteria are coated with a 0.1% PLL and 0.1% alginate solution. Accordingly, the present invention is effective with any microcapsules.
In accordance with another embodiment of the present invention, the encapsulated live bacteria may be suspended in a probiotic acceptable carrier. Such carrier is chosen, without limitation, from a food supplement or food. More preferable, it can be chosen from yogurt, ice cream,
cheese, chocolate, nutritional bars, cereal, milk, infant formulation, fruit juices. In cases of dairy products specially youghurt, its composition such as nutrients (viamines, metal ions, cofactors, proteins, fat contents, sugars, etc) will provide a further protection for the encapsulated live bacterial cells from the gastric fluids and other gastrointestinal environments. MATERIALS AND METHOD
Sodium alginate (low viscosity), poly-L-lysine (MW=27,400) (lot 71 K5120) and calcium chloride (desiccant, 96+%, A.C.S. reagent, FW 110.99, d 2.15, batch # 05614AC) were purchased from Sigma-Aldrich, Canada. MRS AGAR Difco™ Lactobacilli and MRS BROTH Difco™ Lactobacilli were purchased from Becton, Dickinson and Company Sparks, USA. Liberty plain yogurt 2% M. F. containing active Acidophilus and Bifidus cultures was procured from a local store.
Bacteria cultures, propagation and enumeration. L. acidophilus (ATCC 314) cells were inoculated in 10OmL of
MRS broth. The bacteria were then cultured in MRS Broth at 370C in a Professional Sanyo MCO-18M Multi-Gas Incubator. Cultures were grown for 24 hours and centrifuged at 300Ox g for 15 minutes at 370C. The media was decanted; the cells were suspended in 10OmL of fresh MRS media and incubated for an additional 20 hours at 370C. After growth was performed, the resulting cell wet weights were noted. Anaerobic jars and gas generating kits (Atmosphere Generation System AnaeroGen™; Oxoid Ltd., Hampshire, England) were used for creating anaerobic conditions. Microcapsules containing live bacteria were homogenized manually to dilution and plating. Cell count was determined by anaerobic spread plate on MRS agar after 48 hours and was kept constant at 1010 cfu/g throughout the experiment.
Preparation of APA microcapsules loaded with L acidophilus.
APA capsules were prepared aseptically using an lnotech Encapsulator™ IER-20 (lnotech Biosystems Intl. Inc. Switzerland) with a nozzle size of 300μm at a frequency of 1160 Hz, 26.9 syringe pump speed
and a voltage of 1.000 kV using a 60 ml syringe. 60ml of 1.5% (w/v) sodium alginate (low viscosity) was mixed with 3g of harvested bacterial cells (approximate cell load 1010 cfu/g) by centrifuging twice at 300Ox g for 15 minutes with a single wash in 0.85% physiological solution between centrifugations. The formed microcapsules were hardened in 0.1 M calcium chloride solution for 30 minutes, the optimal hardening time (Chandramouli.V. et al., (2004), Journal of microbiological methods 56:27-35). The resulting microcapsules were coated with 0.1 % PLL and 0.1% alginate solution in the same manner as in preparation of APA microcapsules mentioned below. These APA microcapsules loaded with bacterial cells were washed twice with 0.85% physiological solution and stored at 4°C until further use. Preparation of non-loaded APA microcapsule. APA capsules were prepared according to the standard protocol (Sun.A.M.F. et al., (1987), Crc Critical Reviews in Therapeutic Drug Carrier Systems 4:1-12) but with several modifications. Briefly, Ca-alginate beads were exposed to PLL solution (0.1 % w/v) for 10 minutes washed twice with physiological solution (0.85%w/v, pH 7.2); finally put in alginate solution (low viscosity, 0.1 % w/v) for 10 minutes. The resulting APA microcapsules were washed twice with 0.85% physiological solution and stored at 4°C until used. Microcapsule mechanical stability test.
For mechanical stability evaluations, spherical (580 ±26 μm) APA membrane microcapsules were subjected to in vitro mechanical shaking incubation (150 rpm) in MRS broth for 76 hours in a Lab Line Environ Shaker at 37°C. Empty and L. acidophilus loaded APA microcapsules were also exposed to various test fluids: simulated gastric fluid (SGF) and simulated intestinal fluids (SIF), for 3, 12 and 24 hours at 150 rpm shaking and at 370C. Samples were withdrawn and visually analyzed for physical damage using an optical light microscope.
Evaluation of microencapsulated live L. acidophilus cells viability in yogurt.
Over a four-week study, we tested for the survival of encapsulated L acidophilus cells in yogurt. The test samples contained 1Og of APA microcapsules loaded with L acidophilus cells and 1Og of empty APA microcapsules, each immersed in 100 mL of yogurt. Two control samples were set up as follows: 1g of APA microcapsules loaded with L. acidophilus cells in 1OmL of (0.85%, pH 7.2) physiological solution and 1g of empty APA microcapsules in 1OmL of (0.85%, pH 7.2) physiological solution. The microcapsules were filled into 20OmL polyethylene wide mouth dilution tubes in which the bottoms were cut out and replaced with mesh net (200 microns) and placed into 2L polyethylene containers. The microcapsules were trapped to ensure a proper separation from the bacterial cultures of L. acidophilus cells already present in the yogurt when purchased. Before microcapsules were analyzed for the viability of the encapsulated bacterial cells they were washed in (0.85%, pH 7.2) physiological solution 10 times to ensure complete removal of yogurt particulates. All the samples were stored at 40C and exposed to shaking at 100 rpm. Sampling was performed on a weekly basis and photomicrographs were taken at the same time. Microcapsule leakage study
Microcapsule membrane leakage was monitored on a weekly basis by plating the 0.85% physiological solution in which the APA microcapsules loaded with L. acidophilus cells were stored for a period of 4 weeks at 40C. Evaluation of the survival of microencapsulated L. acidophilus cells in different pH environments with and without addition of yogurt
To test for survival of cells in different Gl pH environments, the following buffers were prepared: pH 2 of 0.2M KCI buffer, pH 3 of 0.1 M KHP buffer and pH 4 of 1.0M KHP buffer, pH 6 of 0.1 M KH2PO4 buffer and pH 8 of
0.1 M TRIS buffer. For the experiments 40OmL of each buffer was autoclaved and cooled to room temperature and 10OmL of yogurt was added. The
bottoms of 15m L polyethylene tubes were cut out and replaced with a 200 μm nylon mesh. These modified tubes were then filled up with 10g of L. acidophilus loaded APA microcapsules. Samples were stored in anaerobic conditions at 370C in glass bottles. Sampling under sterile conditions was performed during the following time intervals: 5, 10, 15, 30, 60, 120, 180, 360, 1080, 2520 and 4320 minutes.
In addition, a second survival test was performed in which the above mentioned buffers were loaded with the same microcapsule bacterial load but without the addition of 2% M. F. yogurt. Samples were stored in anaerobic conditions at 370C in glass bottles. Sampling under sterile conditions was performed in the following time intervals: 30, 120, 180, 1080, 2520 and 4320 minutes.
Evaluation of microencapsulated L. acidophilus cells survival in human Gl model-reactor simulating the stomach Microcapsules containing live bacterial cultures L. acidophilus were tested using computer controlled simulated human Gl model. In the model, each of the five reactor vessels represents distinct parts of the human Gl tract in the following order: the stomach, the small intestine, the ascending colon, the transverse colon and the descending colon. In this experiment, 2 hour testing was performed in the first vessel representing the stomach in which a simulated gastric fluid (SGF), a carbohydrate-based diet was composed of arabinogalactan 1.0 g/L, pectin 2.0 g/L, xylan 1.0 g/L, starch 3.0 g/L, glucose 0.4 g/L, yeast extract 3.0 g/L, peptone 1.0 g/L, mucin 4.0 g/L, cystein 0.5 g/L and pH was adjusted with 0.2N HCI was used. 1.5g of APA microcapsules loaded with L. acidophilus was added to 1OmL of SGF fluid and 5mL of yogurt. The control sample was SGF fluid. The study compared the survival of free L acidophilus in SGF fluid only and APA microcapsules loaded with L. acidophilus in SGF fluid but in the absence of yogurt.
Statistical methods
The Microsoft® Excel SP-2 software (Microsoft Corporation, USA) was used for all statistical analysis and the data are presented as mean and standard deviation. RESULTS
Formation of the APA microcapsules
In order to investigate the viability of L. acidophilus cells in various media, a microencapsulation procedure with specific parameters was followed which yielded spherical APA microcapsules of narrow size distribution and a constant bacterial cell load. Fig. 1 displays photomicrographs of freshly encapsulated empty capsules and capsules loaded with L. acidophilus cells. In the photomicrographs, under light microscopy, the capsules reveal their homogeneity, spherical shape and similar size. The empty APA microcapsules appear translucent and L. acidophilus loaded APA microcapsules are opaque owing to a dense load of L. acidophilus cells. Each subsequent microencapsulation yielded a similar bacterial cell load, kept constant at 1010cfu/g.
Mechanical and Gl stability of APA microcapsules
To assure viability of the L. acidophilus cells in the APA microcapsules, the microcapsules need to be resistant to mechanical stress.
Empty and L. acidophilus loaded APA microcapsules were exposed to 200 rpm mechanical in vitro shaking for 76 hours in MRS broth at 370C. Fig. 2 depicts photomicrographs of freshly prepared empty APA microcapsules as well as those loaded with L. acidophilus cells after an incubation period of 76 hours. A study of the APA capsule morphology revealed that no structural damage was visually noticeable; and therefore they were considered suitable for further testing.
An evaluation of the Gl stability of APA microcapsule was carried out by exposing the APA microcapsules containing live LAB cells to simulated gastric fluid (SGF) solution (pH 1.98) at 370C for 3, 12 and 24 hours with 150 rpm mechanical shaking. Microscopic assessment was performed to
evaluate microcapsule integrity. Results show that APA microcapsules were sturdy after exposure and remained intact in SGF for up to 24 hours at pH 1.98 and with 150 rpm shaking (Figs. 3a, 3b and 3c). We also evaluated the APA microcapsule stability in simulated intestinal fluid (SIF) at 370C and with 150 rpm mechanical shaking. The APA membrane was found to have remained intact and microcapsules shown to preserve their original spherical shape after 24 hours. APA microcapsules were seen to swell after 3 hours.
A comparative study wherein APA microcapsules were exposed to a combination of simulated fluids was also performed. Fig. 4 shows the percentage of undamaged APA microcapsules as a function of time; 100% of the APA microcapsules were unchanged after exposure to SGF for 3 hours and SIF for 3 hours. Moreover, no damage was found to occur to the APA microcapsules after treatment for 3 hours in SGF and 12 hours in SIF.
However, up to 3% of the APA microcapsules were found to have been damaged after treatment in SGF for 3 hours and SIF for 24 hours.
The present invention will be more readily understood by referring to the following examples, which are given to illustrate the invention rather than to limit its scope.
EXAMPLE 1 Microencapsulated L. acidophilus cells survival in yogurt and microcapsule permeability study
Studies were designed to investigate APA encapsulated bacterial cell survival in probiotic yogurt. Fig. 5 shows photomicrographs of APA microcapsules loaded with L. acidophilus cells. Pictures Y1 to Y4 were taken weekly over a period of 4 weeks and show APA microcapsules stored in 2% M. F. plain yogurt exposed to mechanical shaking at 100 rpm at 40C. Photomicrographs P1 to P4 show APA microcapsules stored in 0.85% physiological solution, over 4 weeks, stored under similar conditions of 40C and shaking at 100 rpm. This 4-week study revealed that APA microcapsules loaded with L acidophilus cells preserve their shape and integrity over time. The survival of encapsulated L. acidophilus over the 4-week study is shown in
Fig. 6(A). There was a constant drop observed in bacterial cell survival and it reached 7.53 log cfu/g of live bacterial cells after the fourth week of testing. This is however, a rather acceptable loss considering the cell count decreased from 1010 cfu/g to 107 cfu/g, which is usually the minimum requirement for a yogurt to be labeled probiotic. In addition, the mean pH of the yogurt stored at 40C measured on a weekly basis was found to be 4.3.
The capacity of APA microcapsules to retain its cell load was measured over 4 weeks. APA microcapsules loaded with L. acidophilus cells were stored in 0.85% physiological solution at 40C and the supernatant from the medium was plated weekly. Fig. 6(B) shows the percentage survival of live L. acidophilus cells in 0.85% physiological solution over time. A steady increase in the bacterial count was found over 4-weeks. After the fourth week, it was found that 2.21 log cfu/g of L. acidophilus cells had seeped from the APA microcapsules into the storage medium. Survival of microencapsulated L. acidophilus cells in different pH environments with and without supplementation with yogurt
The survival of APA microcapsules loaded with L. acidophilus cells, in various environments, was estimated using a series of different buffers. The viability of encapsulated L. acidophilus cells in the presence of 2% M. F. yogurt in a buffer was tested over 72 hours (Fig. 7). Crucial time points at 120 minutes - the stomach's approximate retention time, and at 360 minutes - the small intestine's retention time showed 6.67 log cfu/g survival at pH 2 and 9.18 log cfu/g viability at pH 6, respectively. As expected, the lowest survival rates were found at the most acidic pH of 2 (5.38 log cfu/g) and at pH 3 (5.52 log cfu/g) after 72 hours. At pH 6 (representative of the small intestine) the viability was seen to be 8.43 log cfu/g after 72 hours, and 6.41 log cfu/g at pH 4. While there was a steep drop in the total bacterial count during the first 3 hours, a slower decline was observed from the 6th hour onward until the 72nd hour. While the L. acidophilus bacterial cultures survived at pH 6 and pH 8, there were no viable cells present at lower pH values beyond the 30 minutes sampling time interval.
Using a computed controlled simulated model of the human Gl tract, a study of the survival of encapsulated bacteria under gastric conditions of pH 1.98 was carried out. Three samples were used; the first, encapsulated L. acidophilus cells in SGF; second, encapsulated L. acidophilus cells in SGF and 2% M. F. yogurt and the third, 2% M. F. yogurt containing free bacterial cultures in SGF. An SGF sample served as a control. During the stomach's 2- hour retention time, the anaerobic survival of L. acidophilus cells at 370C was determined. As shown in Fig. 8, the lowest bacterial count was obtained in the sample containing 2% M. F. yogurt with free bacterial cells in SGF. The highest survival (7.10 log cfu/g) was observed in the sample containing encapsulated L. acidophilus cells in presence of 2% M. F. yogurt and SGF. A slightly lesser survival (6.66 log cfu/g) was determined in the sample containing encapsulated L. acidophilus cells in SGF.
A novel yogurt formulation for oral bacterial delivery using microencapsulation technology was designed in accordance with the present invention. The probiotic bacterium L. acidophilus was encapsulated within APA microcapsule. Any matrix for cell immobilization ideally should provide physical support and uniform distribution of immobilized cells where the transport gradient of nutrients toward and waste products away is balanced and necrosis is prevented. In past studies, it has been reported that the most common type of membrane used for cell therapy is the single alginate based polymer membrane. Various other substances are also being used for encapsulation such as various proteins, polyhemoglobin, and lipids. From a variety of naturally derived membrane materials (e.g. pectin, chitosan, hydroxyethyl methacrylate (HEMA), agarose and lipid complexes), the alginate and poly-L-lysine capsule was selected because alginate is an accepted, generally regarded as safe (GRAS) non-toxic food additive and poly-L-lysine is a natural, safe poly-aminoacid. Calcium ions provide cross- linking with sodium alginate through ionotropic gelation. The PLL coating is shown to provide immunoisolation. The outer alginate layer coating the microcapsules provides better acid stability and improved mechanical
strength. In doing so, the biocompatibility of the multilayer structure is optimized. The molecular weight cut off (MWCO) of the resultant APA membrane was determined to be 60-70 KD, which provides a useful selectivity limit. This would allow the polymer membrane to protect encapsulated materials from harsh external environments, while at the same time allowing for the metabolism of selected solutes capable of passing in and out of the microcapsule.
The microencapsulation technique used yields spherical alginate microcapsules that have a narrow size distribution and retain L acidophilus bacterial cultures (Fig. 1). To be suitable for oral delivery, microcapsules must demonstrate good mechanical resistance and results show that the APA microcapsules maintain their integrity even after prolonged mechanical agitation (Fig. 2). In addition, the APA microcapsules demonstrated excellent resistance to simulated intestinal and gastric fluids and only underwent a slight swelling when exposed to SGF for 3 hours and SIF for 24 hours at 370C with agitation at 150rpm (Fig. 3). As shown in fig. 4, 97% of the microcapsules remain intact after being exposed for 3 hours to SGF and 24 hours to SIF at 150rpm and 370C. Microencapsulated L acidophilus cells were later stored in 2% M. F. yogurt and physiological solution (0.85%, pH 7.2) over 4 weeks. The viability of live L acidophilus in microcapsules and their morphology was monitored. From the photomicrographs, taken weekly, it is seen that the shape of the microcapsules is well preserved and when compared to microcapsules stored in physiological solution, neither the 2% M. F. yogurt nor shaking at 100 rpm alters their integrity or appearance (Fig. 5). Both media, differing significantly in their viscosities (2% M. F. yogurt and 0.85% physiological solution) serve equally well as storage media for APA microcapsules. This implies superior resistance to mechanicalshear and a tolerance to the various components of the simulated Gl fluids. An initial cell load of 107 cfu/g is recommended by National
Yogurt Association for yogurt to be called a probiotic. These high numbers
have been suggested to compensate for the possible loss in the numbers of probiotic organisms during passage through the stomach and intestine. In our studies, a cell load of 1010 (cfu/g) was used. Higher initial load was selected to ensure delivery of a greater number of live bacteria to target sites. Over 4 weeks storage, 7.53 log (cfu/g) of the encapsulated bacteria remained alive with 100 rpm shaking at 40C (Fig. 6(A)). This duration was chosen as it approximates the length of time yogurt can be stored in a refrigerator after purchase. The microcapsule permeability study performed over 4 weeks shows a steady release of the bacteria into the physiological storage solution (0.85% NaCI, pH 7.2). The cumulative count after 4 weeks was found to be approximately 2.21 log (cfu/g) of the encapsulated live bacteria (Fig. 6(B)). Thus the microcapsules seem to retain bacteria adequately.
Bacterial cells encounter a variety of pH's during the period of their Gl transit. The ability to resist and to adapt to these changes is a desirable property in a probiotic. Buffers of various pH values were prepared to mimic the conditions microencapsulated L. acidophilus cells might encounter during passage in the Gl tract. A comparative study was also performed in presence and in absence of 2% M. F. yogurt. Fig. 7 shows the survival rates of microencapsulated L. acidophilus at different pH's in presence of 2% M. F. yogurt.
The survival rates of microencapsulated L. acidophilus in the same conditions without the addition of yogurt were much lower. As expected, after a 72-hour period, the survival at pH 2 was 5.38 log (cfu/g), at pH 3 was 5.52 log (cfu/g), at pH 4 was 6.41 log (cfu/g), at pH 6 was 8.44 log (cfu/g) and at pH 8 was 8.55 log (cfu/g). This shows a lower tolerance and consequently higher sensitivity to extremely acidic environments. As prior results have shown, gastric fluids are detrimental to probiotic cell counts (Lee and Heo, 2000;). It seems however, that encapsulated cells survive gastric conditions significantly better when stored in yogurt as opposed to storage in media sans yogurt.
The survival of free and encapsulated L acidophilus cells in SGF and in the presence and absence of 2% M. F. yogurt was estimated. Fig. 8 shows the survival of encapsulated and free bacteria using a model of a human stomach at 370C over two hours, the time it takes food to pass through the stomach. After two hours, 7.10 log (cfu/g) of microencapsulated L acidophilus cells in the presence of SGF and 2% M. F. yogurt were still alive, while only 5.51 log (cfu/g) of free L acidophilus cells were found to be viable in presence of SGF. In addition, 6.66 log (cfu/g) of microencapsulated L. acidophilus cells in SGF fluid without yogurt were reported alive. The difference in the survival of encapsulated and free bacterial cells could thus, as predicted, be attributed to the protective effect of the APA membrane in the presence of SGF. Moreover, the addition of 2% M. F. yogurt indicates that yogurt might posses some additional protective properties. The protective effect of yogurt on bacterial cells has been attributed to several factors. These include the strains of inherent probiotic bacteria, pH, hydrogen peroxide, storage atmosphere, concentration of metabolites such as lactic acid and acetic acids, dissolved oxygen, and buffers such as whey proteins (Dave, R. I. et al., (1997), International Dairy Journal 7:31-41; Kailasapathy.K et al., (1997), Australian Journal of Dairy Technology 52:28-35). The difference in the survival of microencapsulated L. acidophilus cells in the presence and absence of 2% M. F. yogurt indicates that yogurt may further help protect microencapsulated L. acidophilus cells.
Results show that APA microcapsules display good mechanical stability in storage solutions. This study also demonstrates the protective properties of the APA membrane in low pH conditions, and in simulated gastric fluid. This indicates that ingested microcapsules may be capable of surviving the passage through the stomach and reaching the target sites further in the Gl tract with an adequate cell load which can be further enhanced by using yogurt. In vitro result suggests that yogurt containing APA microencapsulated L acidophilus may represent a significant improvement over ordinary yogurt in the delivery of probiotic bacterial cells for possible
treatment of Gl tract related diseases such as in colon cancer. Further studies, however, are required to substantiate this hypothesis, in particular in vivo confirmation of their effectiveness in experimental animal models.
EXAMPLE 2 Materials and Method
Sodium alginate (low viscosity), poly-l-lysine (MW=27,400) (lot 71K5120) and calcium chloride (desiccant, 96+%, A.C.S. reagent, FW 110.99, d 2.15, batch # 05614AC) were purchased from Sigma-Aldrich, Canada. MRS AGAR Difco ™ Lactobacilli and MRS BROTH Difco Lactobacilli were purchased from Becton, Dickinson and Company Sparks, USA. Chitosan 10 was from Wako Chemicals, Japan. Liberty plain yogurt 0% and 2% M. F. containing active Acidophilus and Bifidus cultures was procured from a local store.
Bacteria cultures, propagation and enumeration L. acidophilus (ATCC 314) cells were inoculated in 10OmL of
MRS broth. The bacteria were cultured in MRS Broth at 370C in a Professional Sanyo MCO-18M Multi-Gas Incubator. Cultures were grown for 24 hours and centrifuged at 300Ox g for 15 minutes at 370C. The media was decanted; the cells were suspended in 10OmL of fresh MRS media and incubated for an additional 20 hours at 370C. After growth was performed, the resulting cell wet weights were noted. Anaerobic jars and gas generating kits (Atmosphere Generation System AnaeroGen™; Oxoid Ltd., Hampshire, England) were used for creating anaerobic conditions. Microcapsules containing live bacteria were homogenized manually to dilution and plating. Cell count was determined by anaerobic spread plate on MRS agar after 48 hours and was kept constant at 1010 cfu/g throughout the experiment.
Preparation of AC microcapsules loaded with L acidophilus
Alginate-Chitosan (AC) microcapsules were prepared aseptically using an lnotech Encapsulate*® IER-20 (Inotech Biosystems Intl. Inc. Switzerland) in a Microzone Biological Containment Hood (Microzone Corporation ON, Canada). The following parameters for microencapsulation were used: a nozzle size of 300μm at a frequency of 918 Hz, 24 syringe pump speed and a voltage of >1.000 kV using a 60 ml syringe. All membrane components were filter sterilized through a 0.22 μm Sterivex-GS filter prior to use. The pellet of wet cells was centrifuged twice at 300Ox g for 10 minutes, weighted and kept constant at 1.7g, suspended in 0.85% saline, pooled and slowly added to a gently stirred 6OmL sterile 1.5% (w/v) sodium alginate (low viscosity) solution. The approximate cell load was kept constant at 1010 cfu/g. Formed microcapsules were hardened in 0.1 M calcium chloride solution for 30 minutes, the optimal hardening time. The resulting microcapsules were coated with 0.5%, 0.25% and 0.1% chitosan 10 solution dissolved in dilute acetic acid at a pH of 5.3 for 30 min. These AC microcapsules loaded with bacterial cells were washed twice with 0.85% physiological solution and stored at 4°C until further use. Preparation of non-loaded AC microcapsule
AC capsules were prepared according to the standard protocol with several modifications. Briefly, Ca-alginate beads were exposed to chitosan solution (0.5% w/v) for 30 minutes, washed twice with physiological solution (0.85%w/v, pH 7.2). The resulting AC microcapsules were washed twice with 0.85% physiological solution and stored at 4°C until used.
Preparation of AC microcapsules
The feasibility of delivering the encapsulated live bacterial cells to various compartments of Gl model was studied. For this, spherical AC microcapsules of narrow size distribution and a constant bacterial cell load were prepared. . Figure 9 displays photomicrographs of freshly encapsulated
empty capsules and capsules loaded with L. acidophilus cells of 550±26 μm in size and magnification of 2.5x using light microscopy. Microcapsules exhibit homogeneous spherical shape. Empty capsules are transparent and capsules loaded with bacterial cells are opaque due to high concentration. Each subsequent microencapsulation yielded a similar bacterial cell load, kept constant at 1010cfu/mL.
Mechanical and Gl stability of AC microcapsules
In order to test microcapsules mechanical stability freshly prepared capsules were subjected to mechanical stress. Fig. (10a) displays empty AC microcapsules, Fig. (10b) - loaded capsules with L. acidophilus and Fig. (10c), same capsules after 76 hours of incubation in MRS broth exposed to mechanical shaking of 150rpm at 370C. It can be observed that the physical morphology of the capsules after being subjected to an intense mechanical stress does not impact capsules integrity or their shape. Upon close examination no damage was noted. Therefore, the capsules preserve their robustness while being exposed to harsh conditions.
Having obtained promising results from physical testing, microcapsules containing bacterial cells were subjected to various fluids found in SHIME (Fig. 11). In addition, all the samples were exposed to mechanical shaking of 150rpm at 370C. All the photomicrographs were taken using magnification of 6.3x. Upon close examination no physical damage was observed and the capsules remained intact.
In Fig. 12, the bars shows 97.42%, 91.11%, 88.43% and
84.19% integrity of AC capsules treated in SGF for 3 hours, SGF and SIF for 3 hours, SGF 3 hours followed by 12 hours in SIF and SGF 3 hours followed by 24 hours in SIF, respectively. As in previous studies, the microcapsules were exposed to mechanical shaking of 150rpm at 370C.
Evaluation of bacterial survival in human Gl model - reactor simulating the stomach
Studies were designed to investigate AC encapsulated bacterial cell survival in probiotic yogurt. Firstly, we compared the survival of encapsulated bacterial cells in SGF with and without addition of 2% M. F. yogurt as well as the survival of free bacteria contained in the yogurt. Fig. 13 shows the predicted results. We anticipated the highest survival rate of AC encapsulated cells in presence of yogurt, which after 120 min. yielded 8.37 log cfu/mL. 7.20 log cfu/mL of viable cells was found of encapsulated L. acidophilus and 7.00 log cfu/g of free bacteria treated with SGF for 120 min.
Evaluation of bacterial survival in human Gl model - reactor simulating the small intestines
Fig. 14 displays survival of AC encapsulated and free bacterial cells obtained by exposure to simulated intestinal fluid conditions. The viability of encapsulated L. acidophilus and free cells in the presence and absence of 2% M. F. yogurt was tested over 6 hours. Crucial time points at 120 minutes - the stomach's approximate retention time, and at 360 minutes - the small intestine's retention time showed 8.05, 7.47, 6.54 and 7.96, 7.09 and 6.24 log cfu/mL, respectively. Evaluation of AC microencapsulated live L. acidophilus cells viability in yogurt
Comparative study measuring the performance of AC microcapsules in yogurt, using chitosan 10, was performed over 4 weeks. AC microcapsules loaded with L acidophilus cells were stored in 2% M. F. yogurt and 0.85% physiological solution at 40C and exposed to mechanical shaking of IOOrpm (Fig. 15). There was a constant drop observed in bacterial cell survival and it reached 9.37 log cfu/mL of cells encapsulated with chitosan 10 and stored in yogurt, 8.04 log cfu/mL of cells encapsulated with chitosan 10 and stored in physiological solution at the fourth week of testing. All the samples were exposed to mechanical shaking of IOOrpm and stored at 40C. In addition, free bacterial cells contained in the yogurt decreased their count
to 7.65 log cfu/mL and 8.26 log cfu/mL for yogurt exposed to mechanical shaking of IOOrpm and yogurt stored at 40C, respectively.
Figure 16 depicts a study performed during 4 weeks where different chitosan 10 concentrations were used, namely 0.5%, 0.25% and 0.1 %. Microcapsules coated with these polymers were stored in 0.85% physiological solution and kept at 40C. Free L. acidophilus cells in 0.85% physiological solution were set up as a control at 40C. A constant drop of bacterial survival was observed over the 4-week study (Fig. 16). The highest survival rate was noticed for chitosan 10 at 0.5% concentration, 9.11 log cfu/mL and the lowest for chitosan 10 at 0.1% concentration - 8.56 log cfu/mL. Free bacterial cells have reached complete downfall at the second week.
Evaluation of the survival of microencapsulated and free L. acidophilus cells in different pH environments with and without addition of yogurt
Another set of experiments was designed to compare the viability of free L. acidophilus cells in 2% M. F. plain yogurt in various buffers with the viability of AC encapsulated bacterial cells during 72-hour study. Figure 17 and 18 show the results. In Figure 17, the highest survival of 6.34 log cfu/mL was read for free L acidophilus cells at pH2, followed by 2.14 log cfu/mL and 1.44 log cfu/tnL at pH3 and 4, respectively. When the cells were exposed to pH6 and 8, they entirely decreased after 360 and 180 min, respectively. On the other hand, bacterial cells did not show complete decline when AC encapsulated and exposed to the same conditions. Figure 18 shows the survival of encapsulated live L acidophilus cells in buffers of pH 2, 3, 4, 6 and 8 supplemented with 2%M.F. yogurt. Contrary to the previous results, cells exhibited the highest survival at pH 8, 10.34 log cfu/mL, and lowest at pH2 of 7.48 log cfu/mL. Moreover, at pH 6 cells reached 10.07 log cfu/mL, at pH 4, 7.56 log cfu/mL and 7.82 log cfu/mL at pH 3. This is consistent with the lactic acid bacteria as they produce lactic acid as a result of carbohydrate
fermentation and their growth lowers both the carbohydrate content of the media that they ferment, and the pH due to lactic acid production.
EXAMPLE 3
Materials and methods Sodium alginate (low viscosity), poly-L-lysine (MW=27,400) (lot
71 K5120) and calcium chloride (desiccant, 96+%, A.C.S. reagent, FW 110.99, d 2.15, batch # 05614AC) were purchased from Sigma-Aldrich, Canada. MRS AGAR Difco ™ Lactobacilli and MRS BROTH Difco ™ Lactobacilli were purchased from Becton, Dickinson and Company Sparks, USA. Liberty plain yogurt 2% M. F. containing active Acidophilus and Bifidus cultures was procured from a local store.
Lactobacillus acidophilus (ATCC 314) cells were cultivated and serially propagated three times in the MRS medium before experimental use. Incubations were performed at 37°C in a Professional Sanyo MCO-18M Multi- Gas Incubator in anaerobic conditions (1-2% CO2, Atmosphere Generation System AnaeroGen™; Oxoid Ltd., Hampshire, England). Bacteria to be encapsulated were isolated after 20 hours of the 3rd passage. Microencapsulation method The bacterial strains were microencapsulated into Alginate-Poly-L- Lysine-Alginate (APA) membranes. All membrane components were filter sterilized through a 0.22 μm Sterivex-GS filter prior to use. Grown cultures were centrifuged at 3000 xg for 15 minutes at 250C and the supernatant broth was decanted. The pellet of wet cells was weighted and suspended in 0.85% saline, pooled and slowly added to a gently stirred sterile 3.3% sodium alginate solution (diluted 50% with 0.85% saline). The entire procedure was performed under sterile conditions in a Microzone Biological Containment Hood (Microzone Corporation ON, Canada) and all solutions were autoclaved with the exception poly-L-lysine which was 0.22 μm sterile-filtered prior to usage. APA microcapsules were prepared aseptically using an lnotech Encapsulator® IER-20 (lnotech Biosystems Intl. Inc. Switzerland). Freshly
prepared microcapsules were washed twice with 0.85% saline and stored at 4°C. Parameters for microencapsulation were as follows:
TABLE 1
Microencapsulator settings
Treatment formulation preparation
APA microcapsules loaded with L. acidophilus bacterial cells were blended with Liberty plain yogurt 2% M. F. and 0.85% saline in the proportions of 1.5:0.5, respectively. Empty APA microcapsules were suspended in 0.85% saline using same formulation.
In vivo mouse colorectal cancer model.
Multiple intestinal neoplasia (Min) mice are heterozygous for ApcM'm+{Miri), a germ-line truncating mutation at codon 850 of the Ape gene and spontaneously develop pretumoric numerous intestinal neoplasms 41. The
Ape (1vlin/+) mouse is a popular animal model for studies on human colorectal cancer 42. It is used to study the effects of genetics, diet, or chemical compounds on the incidence and development of intestinal precancerous lesions, the adenomas 43. The germ-line mutations in the APC gene lead to
FAP, but inactivation of APC is also found in 80% of sporadic colorectal cancers 44.
Male heterozygous C57BL/6J-ApcMιn/+ mice 45, weighing 20-25 g, were obtained from The Jackson Laboratory (Bar Harbor, ME). The animals kept in the Duff Medical Building Animal Care Facility on a 12-hour light-dark cycle and controlled humidity and temperature. They were allowed sterile water and the laboratory rodent diet 5001 from Purina Land O'Lakes ad libitum. Animals overall health was monitored daily.
The protocol was approved by the Animal Care Committee of McGiII University and animals were cared for in accord with the Canadian Council on Animal Care (CCAC) guidelines.
Animal Protocol
Mice 7 or 8 weeks old were used. The life span of these mice is 119 ±
31 days 46. The mice were separated into three experimental groups: 1) Control - animals were gavaged empty APA microcapsules suspended in
0.85% saline, 2) Treatment 1 - animals were gavaged APA microencapsulated L acidophilus bacterial cells blended in 2% M. F. yogurt and 3) Treatment 2 - gavaged APA microencapsulated L. acidophilus bacterial cells suspended in 0.85% saline. Upon arrival, animals were randomly placed in the cages and allowed one week of acclimatization period.
Based on initial serum IL-6 values the animals were ranked and randomly block assigned to the aforementioned groups. There were 11 animals per group. Animals were weighed individually every week; the saphenous vein was bleed every 4 weeks and feces samples were collected at specific intervals throughout the experiment. There were 3 end points at weeks 8, 10 and 12 of treatment at which 9, 9 and 15 animals were sacrificed, respectively.
Analytical techniques.
Interleukin- 6 Determination, lnterleukin-6 (IL-6) is a cytokine secreted by diverse cell types under homeostatic and inflammatory conditions
47. Interleukin (IL)-6 mRNA expression in general is low in normal,
adenomatous and cancerious human colon mucosa; except in rather undifferentiated lesions, in which IL-6 is over expressed. IL-6 has been shown to be associated with cancer development. However, its role in gastric cancer has never been investigated. For this, blood samples were collected every 4 weeks into heperinized tubes which after blood collection were centrifuged at 5000 xg for 20 minutes to yield plasma which was used in further testing. The release of IL-6 from plasma samples into the culture medium was quantified by enzyme-linked mouse immunosorbent assay (ELISA, Biosource, Invitrogen, USA) according to manufacturer's instructions. Briefly, 50 ul plasma plus 50 μL standard diluent buffer were added to each well and incubated for 3 hours and 30 minutes at room temperature. Upon completion of the assay procedure, the plate was read at 450 nm wavelength using a Perkin Elmer Victor microtiter plate reader. The Hemoccult SENSA test. Used according to Beckman Coulter instructions. Briefly, using applicator provided small fecal sample were collected, thin smear was applied covering Box A. Second applicator was used to obtain second sample from a different part of feces, covering Box B. Three days later, samples were developed by applying one drop of Hemoccult SENSA Developer between the positive and negative Performance Monitor areas. Results were read within 10 seconds.
Fecal Bile Acids Determination. Feces were collected at specific intervals throughout the experiment and the analysis was performed per group per cage. Total fecal bile acids were determined as previously described 48, 49 with the following modifications. 25uL of sample were used to determine total bile acid concentration enzymatically as previously described 50 using a commercially available kit (Sigma Diagnostic Bile Acids 450A, Sigma Diagnostics, St. Louis, Missouri, USA).
Adenoma Enumeration, Classification and Histopathology. The mice were euthanised by CO2 asphyxiation, and the small, large intestine and cecum were excised. Upon removal, the intestines were infused with 10%
Phosphate Buffered Formalin (PBF) after which the Swiss Roll was performed by which they were placed in cassettes and immersed in 10% PBF as a fixative. Five-um paraffin-embedded sections were stained with H&E for histological evaluation. Polyp scoring was performed by a blinded veterinary pathologist to the treatment. The lesions observed were divided into two categories mostly based on the size of the lesion: gastrointestinal intraepithelial neoplasia (GIN)(<1mm) and adenoma (>1mm). Statistical Analyses. The Statistical Analysis System (SAS Enterprise Guide 4.1 (4.1.0.471) by SAS Institute Inc., Cary, NC, USA) was used to analyze the data. Data were expressed as means ± SEM. Differences in body weight, IL-6 concentration, adenoma and gastrointestinal intraepithelial neoplasia number between the groups were analyzed statistically by ANOVA Mixed Models. Data were considered significant at P≤O.05.
Microencapsulation and evaluation of the treatment impact on Min mice body weight.
The microencapsulation technique used yielded spherical alginate microcapsules that have a narrow size distribution and retain L. acidophilus bacterial cultures. Fig. 19 displays photomicrographs of freshly encapsulated loaded with L. acidophilus bacterial cells capsules obtained using a light microscopy magnification of 6.3x. They were 433±67 μm in size. Using optimal settings each microencapsulation yielded a fixed bacterial cell load, kept constant in a range of 1010cfu/ml_. After acclimatization period of one week, the animals were randomly block assigned into 3 groups, each composed of 11 animals. Body weights were taken down on weekly basis. (Fig. 20). There was a steady drop of body weight in control group animals, from 24.6±0.48 to 22±1.47 grams over 12 weeks whereas the body weights remained stable in both treatment groups.
Interleukin- 6 level was determined in experimental animals.
Results show the average levels of anti-inflammatory interleukin-6 was
11.17±1.59 for treatment 1 group, 17.45±2.74 for treatment 2 group and
18.33±1.46 pg/mL for the control group at the time of sacrifice (Fig. 21). The expression levels kept increasing in animals of control group and decreasing after the 16th week of age in animals of both treatment groups.
Detection of fecal blood presence in Min mice using the Hemoccult SENSA test.
The feces samples from individual cages were collected at the beginning and end of the experiment. The occult blood test was performed in triplicates. All tests were positive and the coloration intensities from "+" being the least intense to "+++" being the most intense, were qualitatively scored by three observers. The results are displayed in the Table 2. The Hemoccult
SENSA test results in a blue-colored compound which occurs when guaiac is oxidized by hydrogen peroxide. The abnormal bleeding is associated with gastrointestinal disorders and can be qualitatively detected with a higher sensitivity than standard guaiac tests.
TABLE 2
The Hemoccult SENSA test
To determine the effect of microencapsulated probiotic bacteria on luminal bile acids we measured the levels of bile acids in samples of feces from individual cages of each group. There was a constant drop observed in all groups (Fig. 22). The greatest drop of 448±2.82 to 105±21.36 (nmol/g fecal sample/10Og BW) was observed in a group of treatment where animals were gavaged L. acidophilus bacterial cells in APA microcapsules + 0.85% saline.
A decrease of 442±4.87 to 210±3.66 was observed in a treatment group receiving microencapsulated L. acidophilus bacterial cells in 2% M. F. yogurt. The averaged total fecal bile acid values with their respective groups and p values are presented in Table 3.
TABLE 3 Comparison of average total fecal bile acid per group and their p values.
Adenoma reduction in the treated animals: Classification and Histopathology.
The number of adenomas, both with low and high grade dysplasia and gastrointestinal intraepithelial neoplasias (GIN) were scored for each animal group in small and large intestines. The numbers were averaged per animal in a given group. In the large intestines, there was 0.8 of adenomas found in control group versus 0.4 and 0.7 in treatment 1 and 2 groups, respectively (Fig. 23a). In the small intestines, there were 28 of adenomas found in control group versus 13 and 18 in treatment 1 and 2 groups, respectively (Fig. 24a). In the large intestines, there were 0.3 GIN's found in control group versus 0.2
and 0.1 in treatment 1 and 2 groups, respectively (Figure 23b). In the small intestines, there were 8 GIN's found in control group versus 4 and 6 in treatment 1 and 2 groups, respectively (Fig. 24b).
Histological analysis of colon lesions showed that in control the tumors were mostly well differentiated pedunculated adenomas with high grade of dysplasia (Fig. 25a) whereas in mice treated with microencapsulated bacterial probiotic cells the cytological and architectural abnormalities found had either microadenoma, tumors with low grade of dysplasia or broad-based adenoma (Fig. 25 b, c, d). Analysis
Secretion of IL-6 is strongly associated with the pathogenesis of IBD, and overproduction of IL-6 by intestinal epithelial cells is thought to play a part in the pathogenesis of IBD. IL-6 and TNFa can initiate the innate immune response by inducing the acute phase of inflammation. Additionally, IL-6 also appears to be involved in malignant transformation, tumor progression and tumor-associated cachexia, as reported in studies on Kaposi's sarcoma, multiple myeloma, renal cell carcinoma, prostate cancer, ovarian cancer and breast cancer. Although the difference in the average levels of IL-6 between groups is not statistically significant, an overall decreasing trend was observed for both treatment groups. This indicates that an anti-inflammatory state correlates with the beneficial effect of the probiotic on the involved immunomodulatory mechanisms. We did not observe a beneficial effect of bacterial oral administation at the beginning of treatment.
The presence of blood in feces is one of many symptoms that may indicate the presence of polyps in the colon or rectum, or cancer. The Hemoccult SENSA test was performed at the beginning and the end of treatment. The rectal bleeding was observed in animals on arrival and the test was repeated at the end of experiment to verify whether the treatment has an effect to lower the amount of blood detected. This qualitative test detected the presence of blood in the feces in all animal cages at the end of the treatment which does not reveal any significant changes within the groups.
It is known that bile acids contribute to colonic carcinogenesis by disturbing the fine balance between proliferation, differentiation, and apoptosis in colonic epithelial cells. It is also known that secondary bile acids have been implicated as an important etiological factor in colorectal cancer. Bile acids in the feces act as a promoter of colon cancer, in particular deoxycholic acid (DCA), which is one kind of the secondary bile acid. DCA/cholic acid (CA) ratio in feces is also said to have a diagnostic significance in colon cancer.
It is known that lactobacilli are unable to bind the major conjugated bile acid, glycocholic acid (GCA). Further, it is also known that the colonic microflora probably has bile salt hydrolase (BSH) activity which causes the breakdown of conjugated bile acids to the secondary bile acids, most notably DCA. Results show that L acidophilus used in this study had no significant BSH activity. Owing to the fact that DCA is the primary bile acid measured in feces using the total bile analysis kit, the overall decreasing trend indicates that a minor amount of primary bile acids are deconjugated to secondary bile acids. This trend could result on account of replacement of a BSH positive colon flora with one that exhibits lesser BSH activity. Our results indicate that microencapsulated bacterial cells can have an influence in tumorigenesis. The number of adenoma found in each of the treatment groups in the colon and in a small intestine indicates that treatment 1 had a greater impact than treatment 2. However, the number of gastrointestinal intraepithelial neoplasias found in the colon was smaller than in a small intestine. Although there were no statistically significant changes within treatment groups, there was a change between the control and both treatments.
Among all the organs examined in this study there was only one malignant tumor (adenocarcinoma) found in the small intestine of animal from control group. The nuclei were enlarged and pleomorphic with variable loss of their polarity. The glandular structure was distorted and resembled that seen in overt colonic carcinoma. The highest tissue damage was observed in the colon of control group animals under the same conditions as applied to the
other tissues. This is probably due to the fact that the colonic wall, including the mucosa and the submucosa, is much thinner than that of the other organs.
Most of the adenoma found were sessile/broad-based and were composed of papillary projections of lamina propria covered by an epithelium. There was no adenoma or lesions found in removed ceca. The greatest loss in mucin secretion was displayed in severely dysplastic glands of control group animals sacrificed at 12th week of the experiment. The glands were closely packed with one another and their structural atypia, e.g., "back to back" arrangement became more prominent. Nuclei were plump but still uniform and smaller than those in carcinomatous glands. Cytological abnormalities detected included cellular and nuclear pleiomorphism and loss of polarity. Architectural abnormalities were the presence of intraglandular papillary projections and of cribriform and solid epithelial areas. However, there were no major differences in animal tissues collected from animals sacrificed at different time periods. The tumors found in both treatment groups showed some features of papillary carcinoma-grooved nuclei and papillary architecture, but these were not consistent.
The present study demonstrates that microencapsulated probiotic bacteria in yogurt formulation exert promising action on polyp progression by delaying the intestinal inflammation and maintaining the constant body weight of Min mice.
In summary, a novel yogurt formulation with microencapsulated acidophilus was devised for targeted delivery of probiotic bacteria for biotherapy in colon cancer.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosures as come within known or customary practice within the art to which the invention
pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
Claims
1. An oral formulation comprising: a microcapsule containing bacteria; and a fermented milk carrier.
2. The oral formulation according to claim 1 , wherein said microcapsule comprises a semipermeable capsule comprising poly-L-Lysine (PLL) and alginate and wherein the microcapsule is resistant to degradation in gastrointestinal conditions.
3. The oral formulation according to claim 1 or 2, wherein said bacteria are Lactobacilli bacteria or Bifidobacterium bacteria.
4. The oral formulation according to claim 3, wherein said Lactobacilli bacteria are selected from the group consisting of Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum 80, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus Rhamnosus, Lactobacillus GG, Bifidobacterium infantis, Bifidobacterium breve, Bifidobacterium Iongum, Bifidobacterium bifidum.
5. The oral formulation according to any one of claims 1-4, wherein said bacteria are live.
6. The oral formulation according to any one of claims 1-5, wherein said bacteria are present in a range from 109 to 1012 colony forming units per millimeter (CFU/mL).
7. The oral formulation according to any one of claims 1 or 3-6, wherein said microcapsule comprises a material selected from the group consisting of alginate-poly-L-Lysine-alginate (APA), alginate-chitosan (AC), alginate pectinate polylysine pectinate alginate (APPPA), alginate polyethylene glycol alginate (APEGA) and alginate chitosan genipin alginate (ACGA).
8. The oral formulation according to any one of claims 1-7, wherein said fermented milk carrier comprises a basic pH buffer and protects the bacteria and/or the microcapsule from gastrointestinal fluids.
9. The oral formulation according to claim 8, wherein said basic pH buffer is between pH 6-9.
10. The oral formulation according to any one of claims 1-9, wherein said fermented milk carrier comprises a food supplement or food.
11. The oral formulation according to claim 10, wherein said food or food supplement comprises yogurt, cheese, milk, powdered milk, cream, butter, ice cream, kefer or a fermented milk formulation.
12. The oral formulation according to claim 11, wherein said yogurt is selected from the group consisting of plain yogurt, flavored yogurt, yogurt beverage, Dahi, Dadiah, Labneh, Bulgarian Yogurt, Tarator, Cacik, Lassi and Kefir.
13. The oral formulation according to claim 11 or 12, wherein the yogurt comprises 1-10 grams of microencapsulated bacteria per 100 grams of yogurt yogurt, optionally 5-10 grams of microencapsulated bacteria per 100 grams of yogurt, optionally 8-10 grams of microencapsulated bacteria per 100 grams of yogurt.
14. The oral formulation according to claim 11 or 12, wherein the yogurt comprises 4.2 grams of harvested bacteria in 100 mL
15. The oral formulation according to claim 7, wherein wherein the yogurt comprises 4.2 grams of harvested bacteria in 100 ml_ in 1.65% alginate solution.
16. The oral formulation according to claim 1 , for use in nutritional supplementation of a subject or for use in preventing or treating a disease or disorder in a subject.
17. A method for treatment or prevention of a disease or disorder in a subject in need thereof or for nutritional supplementation of a subject, comprising orally administering to the subject the oral formulation of any of claims 1 to 15.
18. Use of the oral formulation of any one of claims 1 to 15 for the preparation of a medicament for the treatment or prevention of a disease or disorder or for the preparation of a nutritional supplement.
19. A fermented milk carrier i) for use as a prebiotic carrier in increasing the efficacy of microencapsulated bacteria in the treatment of a disease or disorder in a subject or ii) for preparation of a medicament for the treatment of a disease or disorder in a subject; wherein optionally the carrier is used in the oral formulation of any one of claims 1-15.
20. The oral formulation, fermented milk carrier, method or use according to any one of claims 14-18, wherein the subject comprises a mammal, optionally a human.
21. The oral formulation, fermented milk carrier, method or use according to any one of claims 14-19, wherein said disease or disorder comprises a gastrointestinal disease or disorder.
22. The oral formulation, fermented milk carrier, method or use according to claim 21 , wherein said gastrointestinal disease or disorder comprises an inflammation gastrointestinal disease or disorder.
23. The oral formulation, fermented milk carrier, method or use according to any one of claims 21 or 22, wherein said gastrointestinal disease or disorder or inflammation gastrointestinal disease or disorder comprises Inflammatory Bowel Disease (IBD), Crohn's Disease colitis, enteroinvasive colitis, Clostridium difficile colitis, Ulcerative Colitis (UC), Inflammatory Bowel Syndrome (IBS), pouchitis, diverticulitis, gastroenteritis, colic, appendicitis, appendicitis, ascending colangitis, esophagitis, gastritis, or enteritis.
24. The oral formulation, fermented milk carrier, method or use according to any one of claims 14-19, wherein said disease or disorder comprises cancer.
25. The oral formulation, fermented milk carrier, method or use according to claim 24, wherein said cancer comprises breast cancer, colorectal cancer, prostate cancer, lung cancer, colon cancer and inflammation-related colon cancer.
26. The oral formulation, fermented milk carrier, method or use according to claim 24, wherein the cancer comprises adenoma, carcinoma, leiomyosarcoma, carcinoid tumor, or squamus cell carcinoma.
27. The oral formulation, fermented milk carrier, method or use according to any one of claims 14-19, wherein said disease or disorder comprises inflammation of tissue in bowel, colon, sigmoid colon, rectum, appendix, anus, esophagus, stomach, mouth, liver, billiary, tract or pancreas.
28. The oral formulation, fermented milk carrier, method or use according to claim 27, wherein said inflammation comprises inflammation of colon.
29. The oral formulation, fermented milk carrier, method or use according to claim 27 or 28, wherein said inflamed tissue or colon comprises increased interleukins and cytokines compared to non-inflamed tissue or colon.
30. The oral formulation, fermented milk carrier, method or use according to any one of claims 27-29, wherein said inflamed tissue or colon comprises up-regulated inflammatory response and markers compared to non-inflamed tissue or colon
31. The oral formulation, fermented milk carrier, method or use according to claim 30, wherein said inflamed tissue or colon comprises increased interleukins such as tumor necrosis factor-α [TNF-α], CD8+, IgA, Mac-1 + and PGE2, interleukin-1 [IL-1], IL-6, IL-12, and γ-interferon in macrophages.
32. The oral formulation, fermented milk carrier, method or use according to any one of claims 14-19, wherein said disease or disorder comprises a urinary tract related disease or disorder.
33. The oral formulation, fermented milk carrier, method or use according to claim 32, wherein said urinary tract related disease or disorder comprises a urinary tract infection or a yeast infection.
34. A method of medical treatment of an inflammatory gastrointestinal disease or disorder in a subject in need thereof, comprising detecting the presence of inflammatory gastrointestinal disease or disorder in the subject, wherein if inflammatory gastrointestinal disease or disorder is detected, then administering the formulation of any one of claims 1 to 15 to the subject.
35. The method of claim 34, wherein the detecting step comprises determining the presence of inflammatory gastrointestinal disease or disorder in the subject with a biopsy of the subject's tissue or a blood test of the subject.
36. The method of claim 35, comprising detection of: elevated C Reactive Protein (CRP), increased Erythrocyte Sedimentation Rate (ESR), elevated neutrophil count, elevated eosinophil count, elevated monocyte count, elevated white blood cell count (WBC), elevated immunoglobulin count or elevated IgA, compared to a subject not having inflammation.
37. The method of any one of claims 34-36, wherein the disease or disorder comprises Inflammatory Bowel Disease (IBD), Crohn's Disease, colitis, enteroinvasive colitis, C. difficile colitis, Ulcerative Colitis (UC), Inflammatory Bowel Syndrome (IBS), pouchitis, diverticulitis, gastroenteritis, colic, appendicitis, appendicitis, ascending colangitis, esophagitis, gastritis, or enteritis.
38. A method of medical treatment of inflammation-related colon cancer in a subject in need thereof, comprising detecting the presence of inflammation- related colon cancer in the subject, wherein if cancer is detected, next administering the formulation of any one of claims 1 to 15 to the subject.
39. The method of claim 38, wherein the detecting step comprises determining the presence of cancer in the subject using fecal occult blood (FOB), visible protrusion adenomatous polyps from the mucosal surface, digital rectal exam, colonoscopy, sigmoidiscopy, abdominal series radiograph with contrast, double contrast enema abdominal radiograph or abdominal CT scan.
40. The method of claim 38, wherein the detecting step comprises determining the presence of cancer in the subject with a blood test of the subject comprising detection of elevated carcinoembryonic antigen (CEA) compared to a subject not having cancer.
41. The method of any one of claims 38-40, wherein the detecting step comprises determining the presence of cancer in the subject with a biopsy of the subject's tissue or a blood test of the subject.
42. The method of claim 41 , comprising detection of: elevated C Reactive Protein (CRP), increased Erythrocyte Sedimentation Rate (ESR), elevated neutrophil count, elevated eosinophil count, elevated monocyte count, elevated white blood cell count (WBC), elevated immunoglobulin count or elevated IgA, compared to a subject not having cancer.
43. The method of any one of claims 38-42 wherein the cancer comprises adenoma or carcinoma.
44. An oral formulation to improve a patient gastrointestinal microflora, which comprises coated microcapsule containing bacteria in suspension in a probiotic acceptable carrier, wherein said coated microcapsule comprises an encapsulated bacteria in a semipermeable capsule coated with poly-L-Lysine (PLL) and alginate and is also resistant in gastrointestinal conditions.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/303,758 US20100028449A1 (en) | 2006-06-06 | 2007-06-06 | Fermented milk product and use thereof |
| EP07719926A EP2046352A4 (en) | 2006-06-06 | 2007-06-06 | Fermented milk product and use thereof |
| CA002654457A CA2654457A1 (en) | 2006-06-06 | 2007-06-06 | Fermented milk product and use thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80400806P | 2006-06-06 | 2006-06-06 | |
| US60/804,008 | 2006-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2007140613A1 true WO2007140613A1 (en) | 2007-12-13 |
Family
ID=38801018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA2007/001010 WO2007140613A1 (en) | 2006-06-06 | 2007-06-06 | Fermented milk product and use thereof |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100028449A1 (en) |
| EP (1) | EP2046352A4 (en) |
| CA (1) | CA2654457A1 (en) |
| WO (1) | WO2007140613A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010079343A3 (en) * | 2009-01-09 | 2010-09-02 | Cambridge Enterprise Limited | Formulations of viable cells for oral delivery |
| WO2010118873A1 (en) * | 2009-04-17 | 2010-10-21 | Kist-Europe | Vector for transporting microbiological organisms to foci of a disease |
| WO2012137072A1 (en) | 2011-04-06 | 2012-10-11 | Biovaxim Limited | Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans |
| WO2012137071A2 (en) | 2011-04-06 | 2012-10-11 | Biovaxim Limited | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
| ITMI20121328A1 (en) * | 2012-07-30 | 2014-01-31 | Probiotical Spa | COMPOSITION FOR MEDICAL DEVICE INCLUDING BACTERIA STRAINS PRODUCERS OF ESOPOLISACCHARIDES IN ASSOCIATION WITH GUMS AND / OR GELATINS. |
| EP3033091A1 (en) * | 2013-08-16 | 2016-06-22 | The University of Hong Kong | Method and compositions for treating cancer using probiotics cross-reference to related application |
| EP3067056A1 (en) | 2009-05-01 | 2016-09-14 | UAS Laboratories LLC | Bacterial compositions for prophylaxis and treatment of degenerative disease |
| CN111201026A (en) * | 2017-10-31 | 2020-05-26 | 株式会社明治 | Fermented milk and polysaccharides having cancer cachexia inhibitory action |
| WO2022041658A1 (en) * | 2020-08-24 | 2022-03-03 | 汤臣倍健股份有限公司 | Bifidobacterium breve 207-1 and use thereof |
| WO2023285691A1 (en) | 2021-07-15 | 2023-01-19 | Allspim | Compositions and methods for preventing and/or treating disease associated with il-23 expression |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITBA20080008A1 (en) * | 2008-02-22 | 2009-08-23 | Michele Barone | COMPOSITIONS INCLUDING SELECTIVE PHYTO-EXTERGENS FOR THE ESTROGENIC BETA AND DIETARY FIBER RECEPTOR |
| EP2452571A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Array of complementary infant/young child nutritional compositions |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| CN102283334A (en) * | 2011-08-31 | 2011-12-21 | 西华大学 | Complex probiotic microcapsule capable of improving intestinal tract micro-ecology of small-sized dogs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| US20130344042A1 (en) * | 2012-06-20 | 2013-12-26 | Gretchen Tanbonliong | Dietary management of celiac disease and food allergy |
| CN104755092A (en) * | 2012-10-30 | 2015-07-01 | 雀巢产品技术援助有限公司 | Compositions comprising microparticles and probiotics to deliver a synergistic immune effect |
| CN102948479A (en) * | 2012-11-19 | 2013-03-06 | 陕西科技大学 | Method for preparing milk beverage containing Bifidobacterium microcapsules |
| US11179427B2 (en) | 2013-01-21 | 2021-11-23 | Eth Zurich | Baby food composition comprising viable propionic acid-producing bacteria |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| WO2015017625A1 (en) * | 2013-07-31 | 2015-02-05 | Wikifoods, Inc. | Encapsulated functional food compositions |
| JP6427278B2 (en) | 2014-12-23 | 2018-11-21 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | pirin polypeptide and immune modulation |
| EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | Methods for restoring microbiota of newborns |
| CN114984057A (en) | 2015-06-15 | 2022-09-02 | 4D制药研究有限公司 | Compositions comprising bacterial strains |
| MA41010B1 (en) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| SI3360559T1 (en) | 2015-06-15 | 2020-02-28 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| RS59446B1 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases |
| EP3209310B1 (en) | 2015-11-20 | 2018-01-31 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11564667B2 (en) | 2015-12-28 | 2023-01-31 | New York University | Device and method of restoring microbiota of newborns |
| CN109069556B (en) | 2016-01-19 | 2022-11-25 | 西姆莱斯有限公司 | Probiotics as anti-inflammatory agents in the oral cavity |
| GB201600975D0 (en) | 2016-01-19 | 2016-03-02 | Probi Ab | Novel strain of probiotic bacteria and compositions and uses thereof |
| EP3196318A1 (en) | 2016-01-19 | 2017-07-26 | Symrise AG | Probiotics for altering the composition of oral biofilms |
| US9999640B2 (en) | 2016-02-02 | 2018-06-19 | University Of Dammam | Microencapsulated probiotic bacteria |
| NZ745678A (en) | 2016-03-04 | 2019-03-29 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TW201821093A (en) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | Compositions comprising bacterial strains |
| EP3351259A1 (en) | 2017-01-18 | 2018-07-25 | Symrise AG | Probiotics for aggregation with disease-associated species in the oral cavity |
| AU2018272291A1 (en) | 2017-05-22 | 2020-01-16 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US20200155622A1 (en) * | 2017-05-22 | 2020-05-21 | Compagnie Gervais Danone | Compositions and methods for decreasing a population of bilophila wadsworthia or inhibiting the growth thereof |
| TW201907931A (en) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | Composition comprising a bacterial strain |
| HUE052319T2 (en) | 2017-06-14 | 2021-04-28 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN111107859B (en) | 2017-06-14 | 2022-04-29 | 4D制药研究有限公司 | Compositions comprising bacterial strains |
| ES2917415T3 (en) | 2017-06-14 | 2022-07-08 | 4D Pharma Res Ltd | Compositions comprising a bacterial strain |
| BR112019028301A2 (en) | 2017-07-05 | 2020-07-14 | Evelo Biosciences, Inc. | compositions and methods for treating cancer using bifidobacterium animalis ssp. lactis |
| CN109007807A (en) * | 2018-08-13 | 2018-12-18 | 上海应用技术大学 | A kind of microcapsules fruit ferment powder and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706287B2 (en) * | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
| WO2004076657A2 (en) * | 2003-02-28 | 2004-09-10 | Mcgill University | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100263822B1 (en) * | 1997-10-14 | 2000-11-01 | 신종훈 | Yorgurt with encapsulated lactic acid bacteria and method for producing the same |
| US20040161422A1 (en) * | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
| DE10134387A1 (en) * | 2001-07-14 | 2003-01-23 | Zeiss Carl | Optical system with several optical elements |
| GB0214705D0 (en) * | 2002-06-26 | 2002-08-07 | Meritor Heavy Vehicle Braking | Pad spring and disc brake incorporating a pad spring |
-
2007
- 2007-06-06 WO PCT/CA2007/001010 patent/WO2007140613A1/en active Application Filing
- 2007-06-06 US US12/303,758 patent/US20100028449A1/en not_active Abandoned
- 2007-06-06 EP EP07719926A patent/EP2046352A4/en not_active Withdrawn
- 2007-06-06 CA CA002654457A patent/CA2654457A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706287B2 (en) * | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
| WO2004076657A2 (en) * | 2003-02-28 | 2004-09-10 | Mcgill University | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
Non-Patent Citations (4)
| Title |
|---|
| CAPELA P. ET AL.: "Effect of cryoprotectants, prebiotics and microencapsulation on survival of probiotic organisms in yoghurt and freeze-dried yoghurt", FOOD RESEARCH INTERNATIONAL, vol. 39, no. 2, March 2006 (2006-03-01), pages 203 - 211, XP005183544 * |
| IYER C. AND KAILASPATHY K.: "Effect of co-encapsulation of probiotics with prebiotics on increasing the viability of encapsulated bacteria under in vitro acidic and bile salt conditions nad in yoghurt", JOURNAL OF FOOD SCIENCE, vol. 70, no. 1, January 2005 (2005-01-01), pages M18 - M23, XP008091811 * |
| KRASAEKOOPT W. ET AL.: "Survival of probiotics encapsulated in chitosan-coated alginate beads in yoghurt from UHT- and conventionally treated milk during storage", LEBENSMITTEL-WISSENSCHAFT UND -TECHNOLOGIE (LWT), vol. 39, no. 2, March 2006 (2006-03-01), pages 177 - 183, XP005067291 * |
| See also references of EP2046352A4 * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010079343A3 (en) * | 2009-01-09 | 2010-09-02 | Cambridge Enterprise Limited | Formulations of viable cells for oral delivery |
| US10016467B2 (en) | 2009-01-09 | 2018-07-10 | Cambridge Enterprise Limited | Formulations of viable cells for oral delivery |
| WO2010118873A1 (en) * | 2009-04-17 | 2010-10-21 | Kist-Europe | Vector for transporting microbiological organisms to foci of a disease |
| EP3067056A1 (en) | 2009-05-01 | 2016-09-14 | UAS Laboratories LLC | Bacterial compositions for prophylaxis and treatment of degenerative disease |
| US10660857B2 (en) | 2009-05-01 | 2020-05-26 | Uas Laboratories Llc | Bacterial compositions for prophylaxis and treatment of degenerative disease |
| WO2012137072A1 (en) | 2011-04-06 | 2012-10-11 | Biovaxim Limited | Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans |
| WO2012137071A2 (en) | 2011-04-06 | 2012-10-11 | Biovaxim Limited | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
| EP3000476A1 (en) | 2011-04-06 | 2016-03-30 | Biovaxim Limited | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
| ITMI20121328A1 (en) * | 2012-07-30 | 2014-01-31 | Probiotical Spa | COMPOSITION FOR MEDICAL DEVICE INCLUDING BACTERIA STRAINS PRODUCERS OF ESOPOLISACCHARIDES IN ASSOCIATION WITH GUMS AND / OR GELATINS. |
| US9889166B2 (en) | 2012-07-30 | 2018-02-13 | Probiotical S.P.A. | Treating low production of mucus in the gastrointestinal tract with S. thermophilus |
| WO2014020408A1 (en) * | 2012-07-30 | 2014-02-06 | Probiotical S.P.A. | Compositions for a medical device comprising exopolysaccharide-producing bacterial strains in association with gums and/or gelatines |
| EP3033091A4 (en) * | 2013-08-16 | 2017-05-03 | Versitech Limited | Method and compositions for treating cancer using probiotics cross-reference to related application |
| EP3033091A1 (en) * | 2013-08-16 | 2016-06-22 | The University of Hong Kong | Method and compositions for treating cancer using probiotics cross-reference to related application |
| CN111201026A (en) * | 2017-10-31 | 2020-05-26 | 株式会社明治 | Fermented milk and polysaccharides having cancer cachexia inhibitory action |
| US11638431B2 (en) | 2017-10-31 | 2023-05-02 | Meiji Co., Ltd. | Fermented milk and polysaccharide with cancerous cachexia inhibitory effect |
| CN111201026B (en) * | 2017-10-31 | 2023-09-19 | 株式会社明治 | Fermented milk and polysaccharides with cancer cachexia inhibiting effect |
| WO2022041658A1 (en) * | 2020-08-24 | 2022-03-03 | 汤臣倍健股份有限公司 | Bifidobacterium breve 207-1 and use thereof |
| US11767503B2 (en) | 2020-08-24 | 2023-09-26 | BYHEALTH Co., Ltd. | Bifidobacterium breve 207-1 and use thereof |
| WO2023285691A1 (en) | 2021-07-15 | 2023-01-19 | Allspim | Compositions and methods for preventing and/or treating disease associated with il-23 expression |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2654457A1 (en) | 2007-12-13 |
| US20100028449A1 (en) | 2010-02-04 |
| EP2046352A1 (en) | 2009-04-15 |
| EP2046352A4 (en) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100028449A1 (en) | Fermented milk product and use thereof | |
| Martín et al. | Faecalibacterium: a bacterial genus with promising human health applications | |
| JP7168558B2 (en) | Treatment of Clostridium difficile infections | |
| Li et al. | Preserving viability of Lactobacillus rhamnosus GG in vitro and in vivo by a new encapsulation system | |
| Grosso et al. | Stability of free and immobilized Lactobacillus acidophilus and Bifidobacterium lactis in acidified milk and of immobilized B. lactis in yoghurt | |
| Patel et al. | New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics | |
| Urbanska et al. | Estimation of the potential antitumor activity of microencapsulated Lactobacillus acidophilus yogurt formulation in the attenuation of tumorigenesis in Apc (Min/+) mice | |
| Rupa et al. | Recent advances in the role of probiotics in human inflammation and gut health | |
| CN101744841B (en) | Bifidobacterium for treating inflammatory disease | |
| Andrade et al. | Commensal obligate anaerobic bacteria and health: production, storage, and delivery strategies | |
| Urbanska et al. | Live encapsulated Lactobacillus acidophilus cells in yogurt for therapeutic oral delivery: preparation and in vitro analysis of alginate–chitosan microcapsules | |
| Marcial-Coba et al. | Dark chocolate as a stable carrier of microencapsulated Akkermansia muciniphila and Lactobacillus casei. | |
| KR20120099663A (en) | Lactobacillus plantarum strains as hypocholesterolemic agents | |
| Song et al. | Improved probiotic viability in stress environments with post-culture of alginate–chitosan microencapsulated low density cells | |
| Vega-Sagardía et al. | Encapsulation, with and without oil, of biofilm forming Lactobacillus fermentum UCO-979C strain in alginate-xanthan gum and its anti-Helicobacter pylori effect | |
| Jin et al. | Effect of gums coating materials on the survival of microencapsulated probiotics under simulated gastrointestinal conditions | |
| Shen et al. | Engineering the microbiome: a novel approach to immunotherapy for allergic and immune diseases | |
| Lee et al. | Effect of pectic oligosaccharide on probiotic survival and physicochemical properties of hydrogel beads for synbiotic encapsulation of Lactobacillus bulgaricus | |
| Zhang et al. | Lactobacillus rhamnosus encapsulated in alginate/chitosan microgels manipulates the gut microbiome to ameliorate salt-induced hepatorenal injury | |
| AboNahas et al. | Trust your gut: the human gut microbiome in health and disease | |
| CN117025488B (en) | Technological method for improving intestinal tract colonization rate of probiotics and probiotics freeze-dried powder | |
| EP4044830A2 (en) | Methods of promoting scfa production by gut microbiota | |
| CN115671067B (en) | Application of Huanglong drop pills in treating and preventing irritable bowel syndrome | |
| CN114057904B (en) | Sulfhydryl radix Codonopsis polysaccharide and application thereof in preparation of colon targeting probiotic microcapsule | |
| Gheisari et al. | Stability of Microencapsulated Lactobacillus Casei in Mango Fruit Juice and its Survival at Simulated Human Gastro-Intestinal Condition. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07719926 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2654457 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007719926 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12303758 Country of ref document: US |